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Abstract 
Problem/Condition: Assisted reproductive technology (ART) includes fertility treatments in which both eggs 
and sperm are handled in the laboratory (i.e., in vitro fertilization and related procedures). Patients who undergo 
ART procedures are more likely to deliver multiple-birth infants than women who conceive naturally. Multiple 
births are associated with increased risk for mothers and infants (e.g., pregnancy complications, premature deliv­
ery, low-birthweight infants, and long-term disability among infants). This report presents the most recent 
national data and state-specific results. 
Reporting Period Covered: 2005. 
Description of System: In 1996, CDC initiated data collection regarding ART procedures performed in the 
United States, as mandated by the Fertility Clinic Success Rate and Certification Act of 1992 (FCSRCA) (Public 
Law 102-493 [October 24, 1992]). Beginning with 2004, CDC has contracted with a statistical survey research 
organization, Westat, Inc., to obtain data from ART medical centers in the United States. Westat, Inc., maintains 
CDC’s web-based data collection system called the National ART Surveillance System (NASS). 
Results: In 2005, a total of 134,260 ART procedures were reported to CDC. These procedures resulted in 
38,910 live-birth deliveries and 52,041 infants. Nationwide, 73% of ART procedures used freshly fertilized 
embryos from the patient’s eggs, 15% used thawed embryos from the patient’s eggs, 8% used freshly fertilized 
embryos from donor eggs, and 4% used thawed embryos from donor eggs. Overall, 42% of ART transfer proce­
dures resulted in a pregnancy, and 35% resulted in a live-birth delivery (delivery of one or more live-born 
infants). The highest live-birth rates were observed among ART procedures that used freshly fertilized embryos 
from donor eggs (52%). The highest numbers of ART procedures were performed among residents of California 
(18,655), New York (12,032), Illinois (9,449), New Jersey (9,325), and Massachusetts (8,571). These five 
states also reported the highest number of live-birth deliveries. Of 52,041 infants born through ART, 49% were 
born in multiple-birth deliveries. The multiple-birth risk was highest for women who underwent ART transfer 
procedures that used freshly fertilized embryos from either donor eggs (41%) or their own eggs (32%). Approxi­
mately 1% of U.S. infants born in 2005 were conceived through ART. Those infants accounted for 17% of 
multiple births nationwide. Approximately 9% of ART singletons, 57% of ART twins, and 95% of ART triplets 
or higher-order multiples were low birthweight. Similarly, 15% of ART singletons, 66% of ART twins, and 97% 
of ART triplets or higher-order multiples were born preterm. 
Interpretation: Whether an ART procedure resulted in a pregnancy and live-birth delivery varied according to 
different patient and treatment factors. ART poses a major risk for multiple births that are associated with adverse 
maternal and infant outcomes (e.g., preterm delivery, low birthweight, and infant mortality). This risk varied 
according to the patient’s age, the type of ART procedure performed, the number of embryos available for transfer 
to the uterus, the number actually transferred, and the day of transfer (day 3 or day 5). 
Public Health Actions: ART-related multiple births represent a sizable proportion of all multiple births nation­
wide and in selected states. To minimize the adverse maternal and child health effects that are associated with 
multiple pregnancies, ongoing efforts to limit the number of 
embryos transferred in each ART procedure should be con-
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Introduction 
Since 1978, assisted reproductive technology (ART) pro­
cedures have been used to overcome infertility. ART proce­
dures include those infertility treatments in which both 
eggs and sperm are handled in the laboratory for the pur­
pose of establishing a pregnancy (i.e., in vitro fertilization 
[IVF] and related procedures). Since the birth of the first 
U.S. infant conceived with ART in 1981, use of these treat­
ments has increased dramatically. Both the number of medi­
cal centers providing ART services and the number of 
procedures performed annually in the United States have 
steadily increased (1). 
In 1992, Congress passed the Fertility Clinic Success Rate 
and Certification Act (FCSRCA),* which requires each 
medical center in the United States that performs ART pro­
cedures to report data to CDC annually on every ART pro­
cedure initiated. CDC uses the data to report medical 
center–specific pregnancy success rates. In 1997, CDC 
published the first surveillance report under this mandate 
(2). That report was based on ART procedures performed 
in 1995. Since then, CDC has continued to publish a sur­
veillance report annually that details each medical center’s 
success rates. CDC also has used this surveillance data file 
to perform more in-depth analyses of infant outcomes (e.g., 
multiple births) (3–10). Multiple-infant births are associ­
ated with greater health problems for both mothers and 
infants, including higher rates of caesarean deliveries, pre­
maturity, low birthweight, and infant death and disability 
(11,12). In the United States, ART has been associated 
with a substantial risk for multiple gestation pregnancy and 
multiple birth (3–10). In addition to the multiple-birth 
risks, studies suggest an increased risk for low birthweight 
among singleton infants conceived through ART (13,14). 
This report is based on ART surveillance data provided to 
CDC’s National Center for Chronic Disease Prevention and 
Health Promotion, Division of Reproductive Health, re­
garding procedures performed in 2005. A report of these 
data, according to the medical center in which the proce­
dure was performed, was published separately (1). In this 
report, emphasis is on presenting state-specific data and 
more detailed data regarding risks associated with ART (e.g., 
multiple birth, low birthweight, and preterm delivery). 
* Fertility Clinic Success Rate and Certification Act of 1992 (FCSRCA), 
Public Law 102-493 (October 24, 1992). 
Methods 
CDC contracted with Westat, Inc., to collect data on 
ART procedures performed in 2005 from medical centers 
in the United States and its territories. Data collected 
include patient demographics, medical history and infer­
tility diagnoses, clinical information pertaining to the ART 
procedure, and information regarding resultant pregnan­
cies and births. The data file is organized with one record 
per ART procedure performed. Multiple procedures from 
a single patient are not linked. Ninety percent of ART 
medical centers reported their 2005 data (1). The names 
of nonreporting programs were published as prescribed by 
the FCSRCA. 
ART data and outcomes from ART procedures are pre­
sented by patient’s state of residence at time of treatment. 
If the patient’s state of residency was missing, the state of 
residency was assigned as the state in which the ART pro­
cedure was performed. In addition, data regarding the num­
ber of ART procedures in relation to the total population 
for each state are indicated.† Data regarding number of 
procedures also are presented by treatment type and stage 
of treatment. ART procedures are classified into four groups 
according to whether the ART cycle involved the retrieval 
and fertilization of eggs (fresh cycle) or the thawing of pre­
viously frozen embryos (frozen cycle), and whether the eggs 
or embryos were those of the intended mother or were from 
a donor. Because both live-birth rates and multiple-birth 
risk vary substantially among these four treatment groups, 
data are presented separately for each type. 
In addition to treatment types, within a given treatment 
procedure, different stages of treatment exist. A typical ART 
procedure begins when a woman starts taking drugs to 
stimulate egg production or her ovaries are monitored with 
the intent of transferring embryos to her uterus. If eggs are 
produced, the procedure progresses to the egg retrieval stage. 
After the eggs are retrieved, they are combined with sperm 
in the laboratory (IVF), and if IVF is successful, the result­
ing embryos are selected for transfer. If the embryo 
implants in the uterus, a clinical pregnancy is diagnosed 
by the presence of a gestational sac detectable by ultra­
sound. Depending on the age of the mother, between 13% 
and 55% of clinical pregnancies are lost at a later point, 
mostly during the 12 weeks (16). Beyond 12 weeks of ges­
tation, the pregnancy usually progresses to a live-birth 
delivery, which is defined as the delivery of one or more 
live-born infants. Only ART procedures involving freshly 
† Data regarding population size are based on July 1, 2005, estimates from 
the U.S. Census Bureau (15). 
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fertilized embryos include an egg-retrieval stage. ART pro­
cedures using thawed embryos do not include egg retrieval 
because eggs were fertilized during a previous procedure, 
and the resulting embryos were frozen until the current 
procedure. An ART procedure can be discontinued at any 
step for medical reasons or by the patient’s choice. 
Although a typical ART procedure includes IVF of 
gametes, culture for >2 days, and embryo transfer into the 
uterus (i.e., transcervical embryo transfer), in certain cases, 
unfertilized gametes (eggs and sperm) or zygotes (early 
embryos [i.e., a cell that results from fertilization of the 
egg by a sperm]) are transferred into the fallopian tubes 
within 1–2 days of retrieval. These are known as gamete 
and zygote intrafallopian transfer (GIFT and ZIFT). 
Another variation is intracytoplasmic sperm injection 
(ICSI), in which IVF is accomplished by selection of a single 
sperm that is injected directly into the egg. This technique 
was developed originally for couples with male factor infer­
tility but now is commonly used for an array of diagnostic 
groups. 
This report presents data for each of the four treatment 
types: freshly fertilized embryos from the patient’s eggs, 
freshly fertilized embryos from donor eggs, thawed embryos 
from the patient’s eggs, and thawed embryos from donor 
eggs. In addition, it provides detailed data for the most 
common treatment type, those using freshly fertilized 
embryos from the patient’s eggs. These procedures account 
for >70% of the total number of ART procedures performed 
each year. For procedures that progressed to the embryo-
transfer stage, the report presents the percentage distribu­
tion of selected patient and treatment factors and the success 
rates (defined as live-birth deliveries per ART-transfer pro­
cedure), according to the same patient and treatment char­
acteristics.
 Patient factors included the age of the woman undergo­
ing ART, whether she had previously given birth, the num­
ber of previous ART attempts, and the infertility diagnosis 
of both the female and male partners. The patient’s age at 
the time of the ART procedure was grouped into five age 
groups: age <35 years, 35–37 years, 38–40 years, 
41–42 years, and >42 years. Infertility diagnoses ranged 
from one factor in one partner to multiple factors in one or 
both partners, as follows: 
• tubal factor — the woman’s fallopian tubes are blocked 
or damaged, causing difficulty for the egg to be fertil­
ized or for an embryo to travel to the uterus; 
• ovulatory dysfunction — the ovaries are not producing 
eggs normally; such dysfunctions include polycystic 
ovarian syndrome and multiple ovarian cysts; 
• diminished ovarian reserve — the ability of the ovary 
to produce eggs is reduced; reasons include congenital, 
medical, or surgical causes or advanced age; 
• endometriosis — involves the presence of tissue similar 
to the uterine lining in abnormal locations; this condi­
tion can affect both fertilization of the egg and embryo 
implantation; 
• uterine factor — a structural or functional disorder of 
the uterus that results in reduced fertility; 
• male factor — a low sperm count or problems with 
sperm function that cause difficulty for a sperm to fer­
tilize an egg under normal conditions; 
• other causes of infertility — immunologic problems or 
chromosomal abnormalities, cancer chemotherapy, or 
serious illnesses; 
• unexplained cause — no cause of infertility was 
detected in either partner; 
• multiple factors, female — diagnosis of one or more 
female cause; or 
• multiple factors, male and female — diagnosis of one 
or more female cause and male factor infertility.
 
Treatment factors included the following:
 
• the number of days the embryo was cultured; 
• the number of embryos that were transferred; 
• whether the procedure was IVF-transfer only, IVF with 
ICSI, GIFT, ZIFT, or a combination of IVF with or 
without ICSI and either GIFT or ZIFT; 
• whether extra embryos were available and cryopreserved; 
and 
• whether a gestational carrier (i.e., surrogate) received 
the transferred embryos with the expectation of gestat­
ing the pregnancy. 
The number of embryos transferred in an ART proce­
dure was categorized as 1, 2, 3, 4, or >5. The number of 
days of embryo culture was calculated using dates of egg 
retrieval and embryo transfer and was categorized as 1, 2, 
3, 4, 5, or 6. Because of limited sample sizes, live-birth 
rates are presented only for the two most common days, 
day 3 and day 5. For the same reason, live-birth rates are 
presented for IVF with and without ICSI and not for GIFT 
and ZIFT. ICSI was subdivided as to whether it was used 
among couples receiving a diagnosis involving male factor 
(the original indication for ICSI treatment) or not. 
Chi-square tests evaluated the significance of differences 
in live-birth rates by select patient and treatment factors 
within each age group. Multivariable logistic regression 
models evaluated the independent effects of patient factors 
(diagnosis, number of previous ART procedures, and num­
ber of previous births) on the chance to have a live birth as 
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a result of an ART treatment. Because patient age is a strong 
predictor for live birth, separate models were constructed 
for each age group; these models provide an indication of 
the variability in live-birth rates based on patient factors 
separately for each age category. For these analyses, the ref­
erent groups included patients with a tubal factor diagno­
sis, no previous ART procedures, and no previous births. 
Multivariable models did not include treatment factors 
because of multicollinearity between certain treatment fac­
tors and multiple potential effect modifications. Rather, 
detailed stratified analyses were performed to elucidate 
additional details related to associations among different 
treatment factors and the live-birth rate. 
In addition to the overall live-birth rate, the report pre­
sents a second measure of success based on the delivery of a 
live singleton. Singleton live births are a key measure of 
ART success because they carry a much lower risk than 
multiple-infant births for adverse health outcomes, includ­
ing prematurity, low birthweight, disability, and death. 
The report addresses multiple birth as a separate out­
come measure. First, each multiple-birth delivery is evalu­
ated as a single event, defined as the delivery of two or 
more infants, at least one of which was live-born. The 
multiple-birth risk thus was calculated as the proportion 
of multiple-birth deliveries among total live-birth deliver­
ies. In additional analyses, each infant in a multiple birth 
was considered separately to compute the proportion of all 
infants born from multiple deliveries and the proportion 
of all live-born infants who were multiples.§ Each of these 
measures represents a different focus. The multiple-birth 
risk, which is based on the number of deliveries or infant 
sets, provides an estimate of the risk of multiple birth posed 
by ART to the woman. The proportion of infants born in a 
multiple-birth delivery provides a measure of the impact 
of ART procedures on children in the population. The 
report presents both measures by type of ART procedure 
and by maternal age for births conceived with the patient’s 
eggs, and provides details on the multiple-birth risk by 
patient’s age, number of embryos transferred, and whether 
additional embryos were available and cryopreserved for 
future use. Embryo availability (an indicator of embryo 
quality) is an independent predictor of the number of em­
bryos transferred (3,6). The report also presents the mul­
tiple-birth risk for embryos cultured through day 3 and 
§ Includes only the number of infants live-born in a multiple-birth delivery. 
For example, if three infants were born in a live-birth delivery and one of 
the three infants was stillborn, the total number of live-born infants 
would be two. However, these two infants still would be counted as 
triplets. 
day 5 by patient’s age, number of embryos transferred, and 
whether additional embryos were available and 
cryopreserved for future use. The proportion of infants born 
in a multiple-birth delivery is presented separately by 
patient’s state of residency at the time of ART treatment. 
Additional analyses evaluated the impact of ART proce­
dures on total births in the United States in 2005. Because 
the goal of the analysis was to assess the effect of ART on 
the 2005 U.S. birth cohort and the ART surveillance sys­
tem is organized according to the date of the ART proce­
dure rather than the infant’s date of birth, these analyses 
employed data drawn from two different ART reporting 
years and covered 1) infants conceived from ART proce­
dures performed in 2004 and born in 2005 (approximately 
two thirds of the live-birth deliveries reported to the ART 
surveillance system for 2004); and 2) infants conceived from 
ART procedures performed in 2005 and born in 2005 
(approximately one third of the live-birth deliveries reported 
to the ART surveillance system for 2005). The U.S. natal­
ity files from CDC’s National Center for Heath Statistics 
provided data on the total number of live births and mul­
tiple births registered in the United States in 2005 (17). 
The report presents the results of these analyses by plural­
ity of birth. 
Additional analyses addressed adverse infant health out­
comes, including low birthweight, very low birthweight, 
and preterm delivery. Because ART providers do not pro­
vide continued prenatal care after a pregnancy is established, 
birthweight and date of birth were collected via active fol­
low-up with ART patients (85%) or their obstetric pro­
viders (15%). Although ART clinic staff collects limited 
information on infant outcomes, maternal health outcomes 
are not investigated systematically. Low birthweight and 
very low birthweight were defined as <2,500 grams and 
<1,500 grams, respectively. The exact gestational age was 
calculated as date of birth minus date of egg retrieval (and 
fertilization). If the date of retrieval was missing, and for 
procedures that used frozen embryos, gestational age was 
calculated as date of birth minus date of embryo transfer. 
For comparability with the general population, which is 
based on the date of the last menstrual period (LMP), the 
exact gestational age was adjusted by adding 14 days to 
the gestational age estimate. Preterm delivery was defined 
as gestational age <37 weeks. Preterm low birthweight was 
defined as gestational age <37 weeks and birthweight 
<2,500 grams. Term low birthweight was defined as gesta­
tional age >37 weeks and birthweight <2,500 grams. The 
rates for low birthweight, very low birthweight, preterm 
low birthweight, and term low birthweight among ART 
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infants born in 2005 are presented by plurality of birth. In 
addition, data for each of the five outcomes are presented 
for ART singletons born in 2005 by type of procedure. For 
the most common procedure type, those using freshly fer­
tilized embryos from the patient’s eggs, the rates for each 
outcome also are presented according to maternal age and 
number of previous live births. Chi-square tests evaluated 
the significance of differences in these five outcomes by 
type of ART procedure, maternal age, and number of pre­
vious births. All analyses were performed using the SAS® 
software system (18). 
Results 
Of 475 medical centers in the United States and sur­
rounding territories that performed ART procedures in 
2005, a total of 422 (90%) provided data to CDC (Figure 
1). The majority of medical centers that performed ART 
procedures were in the eastern United States, in or near 
major cities. The number of medical centers performing 
ART procedures varied by state. The states with the largest 
number of ART medical centers reporting data for 2005 
were California (59), New York (33), Florida (29), Illinois 
(29), and Texas (29). Four states (Alaska, Maine, Montana, 
and Wyoming) and three U.S. territories (Guam, the Fed­
erated States of Micronesia, and the U.S. Virgin Islands) 
had no ART medical centers. 
Number and Type of ART Procedures 
A total of 134,260 ART procedures performed in 2005 
were reported to CDC (Table 1). This number excludes 
358 ART procedures (<1%) performed in 2005 that 
involved the evaluation of a new treatment procedure. The 
largest number of ART procedures occurred among patients 
who used their own freshly fertilized embryos (97,442 [73%]). 
Of the 134,260 procedures started, 112,255 (84%) pro­
gressed to embryo transfer. Overall, 42% of ART proce­
dures that progressed to the transfer stage resulted in a 
pregnancy; 35% resulted in a live-birth delivery; and 24% 
resulted in a singleton live birth. Pregnancy rates, live-birth 
rates, and singleton live-birth rates varied according to type 
of ART. ART procedures that used donor eggs and freshly 
fertilized embryos had the highest success rates (61% preg­
nancy rate, 52% live-birth rate, and 31% singleton live-
birth rate), and procedures using the patient’s eggs and 
thawed embryos had the lowest (36% pregnancy rate, 28% 
live-birth rate, and 22% singleton live-birth rate). 
The 38,910 live-birth deliveries from ART procedures 
performed in 2005 resulted in 52,041 infants (Table 1); 
the number of infants born was higher than the number of 
live-birth deliveries because of multiple-infant births. A total 
of 26,572 singleton infants were born as a result of ART. 
The largest proportion of infants born (36,300 or 70%) 
was from ART procedures in which patients used freshly 
fertilized embryos from their own eggs. 
The two states that had the most ART medical centers 
(California and New York) also had the highest numbers 
of ART procedures performed (Table 2). The largest num­
bers of ART procedures performed in 2005 were among 
residents of California (18,655), New York (12,032), Illi­
nois (9,449), New Jersey (9,325), and Massachusetts 
(8,571). The five states with the largest number of ART 
procedures performed also ranked highest for numbers of 
live-birth deliveries. ART procedures were performed for 
residents of certain states and territories without an ART 
medical center (Alaska, Maine, Montana, Guam, Feder­
ated States of Micronesia, U.S. Virgin Islands, and Wyo­
ming); however, each accounted for a limited percentage 
(<1%) of total ART usage in the United States. Non-U.S. 
residents accounted for <1% of ART procedures, live-birth 
deliveries, and infants born. The ratio of number of ART 
procedures per 1 million population ranged from 108 in 
Puerto Rico to 1,340 in Massachusetts, with an overall 
average of 453 ART procedures started per 1 million persons. 
Characteristics of Patients and ART 
Treatments Among Women Who Used 
Freshly Fertilized Embryos from Their 
Own Eggs 
Forty-five percent of ART transfer procedures that used 
freshly fertilized embryos from the patient’s eggs were per­
formed on women aged <35 years, 24% on women aged 
35–37 years, 19% on women aged 38–40 years, 8% on 
women aged 41–42 years, and 4% on women aged 
>42 years. Patient and treatment characteristics of these 
women varied by age (Table 3). Tubal factor and male fac­
tor infertility were more common among ART procedures 
in women aged <40 years than among procedures in older 
women. In contrast, diminished ovarian reserve, reported 
for only 2% of women aged <35 years, was reported for 
20% of procedures in women aged 41–42 years and 28% 
of procedures in women aged >42 years. Unexplained 
infertility was reported in 9%–15% of ART transfer pro­
cedures, multiple female factors in 9%–16%, and both 
male and female factors in 18%–21%. 
Approximately 65% of ART procedures among women 
aged <35 years were reported as the first ART procedure 
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for that patient. The percentage of ART procedures among 
women who had undergone at least one previous proce­
dure increased with age: only 43% of procedures among 
women aged >42 years were reported as the first procedure 
for that patient. The percentage of procedures performed 
in a woman who had had a previous birth also increased 
with age, from 21% in women aged <35 years to 37% of 
women in the oldest age group.¶ 
The majority of ART procedures used IVF, and <1% used 
GIFT or ZIFT. Use of ICSI was common among couples 
with or without a diagnosis of male factor infertility, and 
varied by patient age. Despite variation among all age 
groups, the total proportion of procedures using ICSI was 
greater than the proportion of IVF without ICSI. 
The majority of procedures included embryo culture for 
3 days; the next most common procedure involved embryo 
culture to day 5. Culture to day 5 often coincides with 
development of the embryo to the blastocyst stage; this 
technique was used more frequently among younger women, 
possibly because ART procedures performed in younger 
women yielded more embryos that can survive in culture 
through day 5. 
The majority of ART procedures involved transfer of more 
than one embryo. Among women aged <35 years, 93% of 
procedures involved the transfer of two or more embryos, 
and 34% involved transfer of three or more embryos. For 
women aged >42 years, 81% involved transfer of two or 
more embryos, and 61% involved transfer of three or more 
embryos. The availability of extra embryos (an indicator of 
overall embryo quality) decreased with age. Extra embryos 
were available and cryopreserved for 45% of procedures 
among women aged <35 years, whereas only 5% of proce­
dures among women aged >42 years yielded extra embryos 
that were cryopreserved. Data were not available regarding 
extra embryos that were not cryopreserved for future use. 
Overall, 1% of ART transfer procedures used a gestational 
carrier or surrogate. 
Live-Birth Rates Among Women Who 
Used Freshly Fertilized Embryos from 
Their Own Eggs 
Live-birth rates for women who underwent ART proce­
dures that used freshly fertilized embryos from their own 
eggs also varied by patient age and selected patient and 
treatment factors (Table 4). Although the average live-birth 
rate for ART-transfer procedures performed among women 
¶ Data were not available to distinguish whether previous births were 
conceived naturally, with ART, or with other infertility treatments. 
who used their own freshly fertilized eggs was 34%, it 
sharply declined with age, from 43% among women aged 
<35 years to 6% among women aged >42 years. Success 
rates did not vary significantly across diagnostic categories. 
Live-birth rates were higher than the age-specific average 
rate for procedures among women aged <35 years whose 
infertility diagnosis was classified as ovulatory dysfunction, 
endometriosis, or male factor infertility, and for procedures 
among women aged >42 years with an infertility diagnosis 
of ovulatory dysfunction or male factor. Live-birth rates 
were lower than average for procedures among women aged 
>42 years with an infertility diagnosis of endometriosis or 
uterine factor. Live-birth rates were lower for procedures in 
women aged <42 years who had undergone a previous ART 
procedure than for first procedures. The system does col­
lect information on whether previous ART procedures were 
successful. Live-birth rates were higher for procedures in 
women who had one or more previous births and had higher 
live-birth rates than for procedures in women with no pre­
vious births. However, this difference was not statistically 
significant for procedures in women aged >40 years. Mul­
tivariable adjustment for patient factors within each age 
strata demonstrated similar patterns (data not presented). 
Live-birth rates were higher for procedures in women who 
had ART procedures that used IVF-ET without ICSI, in 
comparison with procedures that used ICSI, regardless of 
whether male factor infertility was reported (Table 4). In 
all age groups except women aged 41–42 years, live-birth 
rates were lowest for procedures in couples who used ICSI 
in the absence of male factor infertility; however, in all age 
groups, live-birth rates were higher than average for proce­
dures among women who had extended embryo culture to 
day 5, transferred two or more embryos, and had extra 
embryos available and cryopreserved for future use. Varia­
tions in live-birth rates were statistically significant for these 
treatment factors within all age groups. Live-birth rates 
increased in all age groups except for women aged >42 years 
when a gestational carrier was used; however, these results 
did not achieve statistical significance in any age group. All 
of the results for treatment factors need to be considered 
cautiously because treatment was not randomized but rather 
based on medical center assessment and patient choice. 
Thus, comparisons in success rates are prone to confound­
ing by indication. 
Although variability in live-birth rates among patients 
who used different treatment options cannot be completely 
adjusted for determinants of treatment assignment (i.e., 
confounding by indication might remain after adjustment), 
stratified analyses were used to examine associations 
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between treatment factors and live-birth rates among more 
homogenous groups of patients. To address concerns that, 
in the absence of male factor infertility, ICSI might be used 
preferentially for women considered difficult to treat, mul­
tiple groups of patients with poor prognostic profiles were 
evaluated separately (data not presented). These groups 
included women who underwent previous ART cycles but 
had no previous pregnancies or births, women diagnosed 
with diminished ovarian reserve, and women with fewer 
than five eggs retrieved. Within each of these groups, age­
specific–live-birth rates for IVF-ET with and without ICSI 
were examined. In all analyses, except for women 
aged >42 years with less than five eggs retrieved, women 
who used IVF with ICSI had lower success rates than 
women who used IVF without ICSI; the pattern of these 
results (data not presented) is consistent with the findings 
presented in this report (Table 4). Data regarding women 
deemed to have a higher probability of success (i.e., women 
with more than 10 eggs retrieved, women with diagnoses 
other than diminished ovarian reserve, and women with 
extra embryos cryopreserved for future use) were evaluated 
separately (data not presented) to adjust for the possibility 
that day 5 embryo transfers might have been used prefer­
entially for women with better prognoses. Within each of 
these subgroups, age-specific–live-birth rates were lower 
for embryo transfers on days 1–4 compared with day 5 
transfers. Finally, additional analyses were stratified by 
patient age, number of embryos transferred, day of embryo 
transfer (day 3 or day 5), and number of embryos available 
simultaneously. These results are included with the discus­
sion regarding multiple-birth risk. 
Total live-birth rates were compared with singleton live-
birth rates for procedures employing freshly fertilized 
embryos from the patient’s eggs (Figure 2). Both live-birth 
rates and singleton live-birth rates decreased with patient 
age. Across all age groups, singleton live-birth rates were 
lower than live-birth rates. However, the magnitude of the 
difference between these two measures declined with 
patient age. 
Multiple-Birth Risks Associated with ART 
Of 12,338 multiple-birth deliveries, 8,662 (70%) were 
from pregnancies conceived with freshly fertilized embryos 
from the patient’s eggs, 1,199 (10%) were from thawed 
embryos from the patient’s eggs, 2,059 (17%) were from 
freshly fertilized embryos from a donor’s eggs, and 418 (3%) 
were from thawed embryos from a donor’s eggs (Table 5). 
In comparison with ART procedures that used the patient’s 
eggs and freshly fertilized embryos, the risks for multiple-
birth delivery were increased when eggs from a donor were 
used and decreased when thawed embryos were used. Among 
ART procedures in which freshly fertilized embryos from 
the patient’s own eggs were used, a strong inverse relation 
existed between multiple-birth risk and patient age. The 
average multiple-birth risk for ART procedures in which 
freshly fertilized embryos from the patient’s eggs were used 
was 32%. The multiple-birth risk varied from 36% among 
women aged <35 years to 13% among women aged 
>42 years. 
Of 52,041 infants born through ART, 49% (25,469) 
were born in multiple-birth deliveries (Table 5). The pro­
portion of infants born in a multiple-birth delivery also 
varied by type of ART procedure and patient age. Among 
ART transfer procedures in which the patient used freshly 
fertilized embryos from their own eggs, the proportion of 
infants born in a multiple-birth delivery ranged from 53% 
in women aged <35 years to 23% in women aged >42 years. 
Among ART transfer procedures in which thawed embryos 
from the patient’s eggs were used, the proportion of infants 
born in a multiple-birth delivery ranged from 40% in 
women aged <35 years to 21% in women aged >42 years. 
When thawed embryos from donor eggs were used, the 
proportion of infants born in a multiple-birth delivery was 
43%. The proportion of infants born in a multiple-birth 
delivery was highest (59%) in women who used freshly 
fertilized embryos from donor eggs. 
A more detailed examination of multiple-birth risk for 
ART procedures employing freshly fertilized embryos from 
the patient’s own eggs revealed that the number of 
embryos transferred was a key risk factor for multiple-birth 
delivery, but that the magnitude of the association varied 
by patient age (Table 6). Among all age groups, transfer of 
two or more embryos was associated with increased live-
birth delivery rates. However, the multiple-birth risk also 
was increased substantially. Among women aged <37 years, 
the percentage of triplet or higher-order deliveries increased 
steadily with increasing number of embryos transferred from 
two to five or more. For women aged 38–40 years, the per­
centage of twin deliveries increased steadily with the num­
ber of embryos transferred. This trend was not apparent 
for procedures in women aged >40 years, possibly because 
women in these age groups have embryos with reduced 
implantation potential and therefore are less likely to have 
multiple births. 
Additional analyses addressed multiple-birth risk among 
patients who used freshly fertilized embryos from their own 
eggs and set aside extra embryos for future use (Table 6). 
These patients can be thought of as those with elective 
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embryo transfer because they chose to transfer fewer 
embryos than the total number that were available. For 
procedures in women with elective embryo transfer who 
were aged <35 years, live-birth rates were 43% when only 
one embryo was transferred and 53% when two embryos 
were transferred. The higher live-birth rate after transfer of 
two embryos was associated with a large increase in the 
multiple-birth risk (38.5% compared with 1.9% after single 
embryo transfer). 
For procedures in women aged 35–37 years, live-birth 
rates were 39% with elective embryo transfer of a single 
embryo and 47% when two embryos were transferred. As 
in the younger age category, the higher live-birth rate after 
transfer of two embryos was associated with a large increase 
in the multiple-birth risk (32.7% compared with 2.1% 
after single embryo transfer).** 
Among patients who used freshly fertilized embryos from 
their own eggs, the live-birth rates and multiple-birth risks 
typically were higher for embryo transfers on day 5 than 
on day 3 (Table 7). Overall, across all age groups, fewer 
embryos were transferred on day 5 than on day 3. For 
example, among women aged <35 years, two or fewer 
embryos were transferred in 86% of day 5 transfers and in 
57% of day 3 transfers. Similarly, in women aged <35 years, 
92% of day 5 elective transfers and 67% of day 3 elective 
transfers involved the transfer of two or fewer embryos. As 
noted previously, both live-birth rates and multiple-birth 
risks were higher for patients who had elective embryo trans­
fers. For women with elective embryo transfer on day 5 
who were aged <35 years, the percentage of transfers 
resulting in live births was 48% when one embryo was 
transferred and 58% when two embryos were transferred. 
By contrast, the multiple-birth risks in these two groups 
were 3% and 44%, respectively. Thus, the 10% increase in 
the live-birth rate was accompanied by a 41% increase in 
the risk for a multiple delivery. If success is measured in 
terms of singleton live-birth, the highest success rates for 
this group were with one embryo transferred. This also was 
true for women aged 35–37 years with elective single 
embryo transfers on day 5 (Table 7). 
The states with the highest number of ART-associated 
live-birth deliveries also had the highest number of infants 
born in multiple-birth deliveries (Table 8). These include 
California (3,635), New York (1,768), New Jersey (1,692), 
Texas (1,666), Illinois (1,501), and Massachusetts (1,293). 
** Results are based on total multiple-birth risk and therefore do not 
provide an indication of pregnancies that began as twins, triplets, or a 
higher order but reduced (either spontaneously or through medical 
intervention) to singletons or twins (Tables 6 and 7). 
Nationwide, the percentage of ART-born infants who were 
born in multiple-birth deliveries was 49%; the percentage 
of twins was 44% and that of triplets or higher-order mul­
tiples was 5%. The percentage of ART-born infants in 
multiple-birth deliveries was >50% in the majority of states. 
The states with the highest proportion of ART-born 
infants in multiple-birth deliveries were New Mexico 
(56%), Utah (56%), Oregon (56%), Montana (56%), 
Idaho (54%), Texas (54%), Alabama (54%), and Kansas 
(54%); however, these findings should be interpreted with 
caution because of an overall low number of live births 
resulting from ART in certain states. 
Of 4,138,349 infants born in the United States in 2005, 
a total of 49,308 (1%) were conceived with ART (Table 9). 
Infants conceived with ART accounted for 0.6% of single­
ton births and 17% of multiple births nationwide; 16% of 
all twins and 38% of infants born in triplets or higher-
order multiples were conceived with ART. 
Perinatal Risks Associated with ART 
The percentage of infants with low birthweight varied 
from 9% among singletons to 95% among triplets or 
higher-order multiples. The percentages of very low 
birthweight, preterm, and preterm low birthweight fol­
lowed similar patterns (Table 10). 
The percentages of ART singletons that were low 
birthweight and preterm varied by procedure type and 
selected maternal factors (Table 11). In comparison with 
singletons born after procedures that used freshly fertilized 
embryos derived from the patient’s eggs, singletons born 
after procedures that used freshly fertilized embryos 
derived from donor eggs were at increased risk for three 
perinatal outcomes: low birthweight, preterm delivery, and 
preterm low birthweight. Singletons born after procedures 
that used thawed embryos were at decreased risks for low 
birthweight and term low birthweight; however, they were 
at increased risk for preterm delivery overall. The variation 
in risk across procedure types was not statistically signifi­
cant for very low birthweight and preterm low birthweight. 
More detailed analysis of maternal factors among single­
tons born after procedures that used freshly fertilized em­
bryos derived from the patient’s eggs indicated higher risks 
of low birthweight, very low birthweight, preterm deliv­
ery, and preterm low birthweight for women aged 
41–42 years. Higher risks for low birthweight and term 
low birthweight were observed among mothers with no pre­
vious births; the variation in risks was statistically signifi­
cant (p<0.01) for both of these outcomes. 
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Discussion 
According to the most recent estimates of infertility in 
the United States, 10% of women of reproductive age 
(15–44 years) reported a previous infertility-associated 
health-care visit, and 2% reported a visit during the previ­
ous year (19). Among married couples in which the woman 
was of reproductive age, 7% reported they had not con­
ceived after 12 months of unprotected intercourse. With 
advances in ART, couples are increasingly turning to this 
form of treatment to overcome their infertility. 
Since the birth of the first infant through ART in the 
United States in 1981, use of ART has grown substantially. 
The use of ART has consistently increased in the United 
States since 1996, when CDC began ART surveillance. The 
increased use of ART, coupled with higher ART success 
rates, has resulted in dramatic increases in the number of 
children conceived through ART each year. The number of 
ART procedures reported to CDC has more than doubled, 
from 64,681 in 1996 to 134,260 in 2005 (1). During the 
same period, the number of infants conceived through ART 
procedures more than doubled, from 20,840 to 52,041. 
This report documents that in 2005, ART use varied 
according to the patient’s state of residency. Residents of 
California, New York, Illinois, New Jersey, Massachusetts, 
and Texas reported the highest number of ART procedures. 
These states also reported the highest number of infants 
conceived through ART. In 2005, ART use by state of resi­
dency was not completely in line with expectations based 
on the total population within states (15). Whereas 
Massachusetts had the fifth highest number of ART proce­
dures performed, it ranked fourteenth in total population 
size.†† Similarly, residents of District of Columbia, Rhode 
Island, and Hawaii underwent more ART procedures than 
would have been expected based on their population sizes. 
As a result, state-specific ratios of ART procedures by popu­
lation varied according to state of residency. The highest 
ratios of the number of ART procedures among state resi­
dents per 1 million population were observed in 
Massachusetts (1,340), District of Columbia (1,166), New 
Jersey (1,070), Maryland (837), Connecticut (783), and 
Rhode Island (774). This divergence is not unexpected 
because, in 2005, Connecticut, Massachusetts, New Jersey, 
and Rhode Island had statewide mandates for insurance 
coverage for ART procedures. Variation within states also 
might be related to availability of ART services within each 
state. However, the relation between demand for services 
†† Data regarding population size are based on July 1, 2005, estimates 
from the U.S. Census Bureau (15). 
and availability cannot be disentangled (e.g., increased avail­
ability in certain states might reflect the increased demand 
for ART among state residents). 
Among women who used fresh fertilized embryos from 
their own eggs, patient factors (e.g., infertility diagnoses, 
history of previous ART procedures, and previous births) 
varied considerably by age. The proportion of procedures 
in which the couple received a diagnosis of ovulatory dys­
function, endometriosis, or male factor infertility decreased 
with the woman’s age, whereas the proportion of proce­
dures in which the couple received a diagnosis of dimin­
ished ovarian reserve increased with the woman’s age. History 
of previous ART and previous births were more common 
among older women. In addition, treatment factors varied 
considerably by the age of the woman. The proportion of 
procedures in which embryo transfer occurred on day 5 
(i.e., the blastocyst stage) declined with the age of the 
woman, whereas the proportion of procedures in which 
three or more embryos were transferred increased steadily 
with age. 
Because ART success rates are affected by multiple 
patient and treatment factors, using a single measure of 
success is not sufficient to evaluate ART efficacy. At a mini­
mum, ART procedures should be subdivided on the basis 
of the source of the egg (patient or donor) and the status of 
the embryos (freshly fertilized or thawed) because success 
rates vary substantially across these types. Within the type 
of ART procedure, further variation exists in success rates 
by patient and treatment factors, most notably patient age. 
Other factors to consider when assessing success rates are 
infertility diagnosis, number of previous ART procedures, 
number of previous births, method of embryo fertilization 
and transfer, number of days of embryo culture, number of 
embryos transferred, availability of extra embryos, and use 
of a gestational carrier (i.e., surrogate). Variation exists in 
success rates according to each of these factors. 
CDC’s primary focus in collecting ART data has been on 
live-birth deliveries as an indicator of success because ART 
surveillance activities were developed in response to a fed­
eral mandate to report ART success rate data. This man­
date requires that CDC collect data from all ART medical 
centers and report success rates, defined as all live births 
per ovarian stimulation procedures or ART procedures, for 
each ART medical center. Therefore, a key role for CDC 
has been to publish standardized data related to ART suc­
cess rates, including information regarding factors that 
affect these rates. With these data, persons and couples can 
make informed decisions regarding whether to undergo this 
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time-consuming and expensive treatment (20).§§ However, 
success-rate data also should be balanced with consider­
ation of effects on maternal and infant health. CDC 
receives data on pregnancy outcomes of public health sig­
nificance, which enables CDC to monitor multiple-birth 
rates, preterm delivery, and low birthweight associated with 
ART. 
In the United States, multiple births have increased sub­
stantially since the 1980s (17,21). The increase in mul­
tiple births has been attributed to an increased use of ART 
and delayed childbearing (5,22,23). Although infants con­
ceived with ART accounted for 1% of the total births in 
the United States in 2005, the proportion of twins and 
triplets or higher-order multiples attributed to ART were 
16% and 38%, respectively. In 1999, the Society for 
Assisted Reproductive Technology and the American Soci­
ety for Reproductive Medicine issued voluntary guidelines 
(24) on the number of embryos transferred; these guide­
lines were revised in 2004 (25) and 2006 (26). 
In certain states, ART procedures are not covered by 
insurance carriers, and patients might feel pressured to maxi­
mize the opportunity for live-birth delivery. In addition, if 
success is defined solely as total live-birth delivery, anec­
dotal evidence suggests that certain ART providers might 
feel pressure to transfer multiple embryos to maximize their 
publicly reported success rates (27). In the United States, 
multiple embryo transfer was still a common practice in 
2005; approximately 47% of ART procedures that used 
fresh, nondonor eggs or embryos and progressed to the 
embryo-transfer stage involved the transfer of three or more 
embryos. Approximately 18% of procedures involved the 
transfer of four or more, and 6% of procedures involved 
the transfer of five or more embryos (1). Among women 
aged <35 years, the proportion of ART procedures that 
involved four or more embryos transferred was approximately 
8% because women in this age category typically experi­
ence higher success rates with fewer embryos transferred. 
Multiple scientific reports have advocated that singleton 
live-birth rates be presented as a distinct indicator of ART 
success (28–34). This report includes this measure 
(Figure 2) and presents it with total live-birth rates. Suc­
cess rates based on singleton live-birth deliveries will pro­
vide patients with a measure that more directly highlights 
infant outcomes with the optimal short- and long-term 
prognosis. Twins, albeit to a lesser extent than triplets or 
higher-order multiples, have substantially increased risks 
for infant morbidity and mortality. The risks for low 
§§ Estimated cost for one procedure of IVF averages $12,400 (20). 
birthweight and preterm birth both exceed 57% for twins, 
and the risk for very low birthweight is 9% (17). In addi­
tion, because twins are at substantially increased risk for 
perinatal and infant mortality (11,21), singleton live-birth 
rates are a valid measure of success. 
Data in this report indicate that 49% of infants born 
through ART in 2005 were born in multiple–birth deliv­
eries, compared with 3% in the general U.S. population 
(17). The twin rate was 44%, compared with 3% in the 
general U.S. population, and the rate of triplets and higher-
order multiples was 5%, approximately 25 times higher 
than the general U.S. population rate (0.2%). Regarding 
the specific type of ART procedure, the percentage of 
infants born in multiple-birth deliveries were among the 
highest for women who underwent ART procedures that 
used freshly fertilized embryos from their own eggs (49%) 
or from donor eggs (59%). 
In 26 states, District of Columbia, and Puerto Rico, 
>50% of infants conceived through ART were born in 
multiple-birth deliveries. Multiple births resulting from 
ART are an increasing public health concern, nationwide 
and for the majority of states. 
For women who underwent ART procedures using freshly 
fertilized embryos from their own eggs, the multiple-birth 
risk increased when multiple embryos were transferred. 
Embryo availability, an indicator of embryo quality, also 
was a strong predictor of multiple-birth risk independent 
from the number of embryos transferred. In analyses strati­
fied by patient age, number of embryos transferred, day of 
embryo culture (day 3 or 5), and embryo availability, high 
live-birth rates and singleton live-birth rates were achieved, 
particularly among younger women as transfer of a single 
embryo was efficacious. In the majority of groups, limiting 
the number of embryos transferred can minimize the 
multiple-birth risk without severely compromising the suc­
cess rates. 
In addition to the known multiple-birth risks associated 
with ART, singleton infants conceived from ART proce­
dures are at increased risk for low birthweight and preterm 
delivery. In 2005, of all singleton infants conceived with 
ART, 9% were low birthweight, compared with 6% in the 
general U.S. population (16). Approximately 2% of single­
ton infants conceived from ART were very low birthweight, 
compared with approximately 1% of singletons conceived 
in the general U.S. population. The percentage of ART 
singletons born preterm was higher than the general U.S. 
population (15% and 11%, respectively). Thus, adverse 
infant health outcomes among singletons (e.g., low 
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birthweight and preterm delivery) also should be consid­
ered when assessing the efficacy and safety of ART. 
A comparison of perinatal outcomes among ART twins 
and triplets or higher-order multiples with their counter­
parts in the general population is not useful for at least two 
reasons. First, both ART and non-ART infertility treatments 
are estimated to account for a substantial proportion of 
multiple births in the United States, and distinguishing 
naturally conceived from iatrogenic multiple births is not 
possible. ART accounts for only 1% of the total U.S. births; 
however, it accounts for 16% of twins and 38% of triplets 
or higher-order multiples. Second, the majority of mul­
tiple births conceived after ART treatment are likely dizy­
gotic from multiple embryo transfer. Among natural 
conceptions, approximately one third to one half of twins 
might be monozygotic, depending on maternal age (35). 
Monozygotic twins are at increased risk for adverse out­
comes in comparison with dizygotic twins (36). 
Multiple births are associated with an increased health 
risk for both mothers and infants (11,12,20,22). Women 
with multiple-gestation pregnancies are at increased risk 
for maternal complications (e.g., hemorrhage and hyper­
tension). Infants born in a multiple-birth delivery are at 
increased risk for prematurity, low birthweight, infant 
mortality, and long-term disability. 
The contribution of ART to preterm births in the United 
States also is a key concern. This report documents that 
approximately 42% of ART infants born in 2005 were 
preterm (Table 10), compared with approximately 13% of 
preterm births in the general U.S. population (17). Preterm 
infants have increased risk of death and have more health 
and developmental problems than full-term infants 
(37–40). The health risks associated with preterm births 
have contributed to increasing health-care costs. The eco­
nomic burden associated with preterm births in the United 
States in 2005 has been estimated to be $26 billion 
($51,600 per infant born preterm) (40). ART infants born 
preterm accounted for approximately 4% of all preterm 
births in the United States in 2005, a total economic bur­
den estimated at $1 billion. ASRM and SART guidelines 
on the number of embryos transferred in an ART cycle 
might help in further reducing the incidence of preterm 
deliveries, the majority of which are multiples. 
The findings in this report are subject to several limita­
tions. First, ART surveillance data were reported for each 
ART procedure performed rather than for each patient who 
used ART. Linking procedures among patients who under­
went more than one ART procedure in a given year is not 
possible. Because patients who underwent more than one 
procedure in a given year were most likely to include those 
in which a pregnancy was not achieved, the success rates 
reported might underestimate the true per-patient success 
rate. In addition, ratios of ART procedures per population 
might be higher than the unknown ratio of the number of 
persons undergoing ART per population. Second, these data 
represent couples who sought ART services in 2005; there­
fore, success rates do not represent all couples with infertil­
ity who were potential ART users in 2005. Third, because 
treatment was not randomized but rather based on medi­
cal center assessment and patient choice, results for treat­
ment factors must be considered with caution. Finally, 
approximately 11% of medical centers that performed ART 
in 2005 did not report their data to CDC as required. 
ART data are reported to CDC by the ART medical cen­
ter in which the procedure was performed rather than by 
the state in which the patient resided. In this report, ART 
data are presented by the female patient’s state of residence. 
Residency data were missing for approximately 8% of all 
live-birth deliveries resulting from ART procedures started 
in 2005. In cases of missing residency data, residency was 
assigned as the state in which the ART procedure was per­
formed. Thus, the number of procedures performed among 
state residents, number of infants, and number of multiple-
birth infants might have been overestimated for certain 
states. Concurrently, the numbers might be underestimated 
in states that border states with missing residency data, 
particularly states in the Northeast region of the United 
States. Nonetheless, the effects of missing residency data 
were not substantial. Statistics were evaluated separately 
according to the location of the ART medical center rather 
than the patient’s state of residence. The rankings of the 
ART medical center location by total number of infants 
and multiple-birth infants were similar to the rankings based 
on patient’s state of residence (data not presented). 
The patient’s state of residence was reported at the time 
of ART treatment. The possibility of migration during the 
interval between ART treatment and birth exists. U.S. Cen­
sus Bureau data indicate that approximately 3% of the U.S. 
population moves between states annually; this rate is even 
higher for persons aged 20–34 years (41). 
Members of the U.S. armed forces have a high potential 
for migration. Therefore, ART procedures performed among 
patients who attended military medical centers were evalu­
ated separately. In 2005, 0.7% ART procedures were per­
formed in four military medical centers (California, District 
of Columbia, Hawaii, and Texas). In certain facilities, a 
substantial number of distinct states were listed for patient’s 
state of residence. States and territories for which >1% of 
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ART procedures among residents were performed in a mili­
tary medical center were Alaska, Delaware, District of 
Columbia, Guam, Hawaii, Kansas, Maryland, New Mexico, 
North Carolina, Oklahoma, South Carolina, Texas, Virginia, 
and Wyoming. States for which >5% of ART procedures 
among state residents were performed in a military medi­
cal center were District of Columbia, Guam, and Hawaii. 
Despite these limitations, findings from national surveil­
lance of ART procedures performed in the United States 
provide useful information for patients contemplating ART, 
ART providers, and health-care policy makers. ART sur­
veillance data can be used to monitor trends in ART use 
and outcomes from ART procedures. Data from ART sur­
veillance can be used to assess patient and treatment fac­
tors that contribute to higher success rates. Ongoing 
surveillance data can be used to assess the risk for multiple 
births and adverse perinatal outcomes among singleton 
births. Surveillance data provide information to assess 
changes in clinical practice related to ART treatment. 
Increased use of ART procedures and the practice of trans­
ferring multiple embryos during ART treatments have led 
to high multiple-birth rates in the United States (5,10). 
Balancing the chance of success of ART against the risk for 
multiple births is challenging. Implementation of ap­
proaches to limit the number of embryos transferred for 
patients undergoing ART should reduce the occurrence of 
multiple births resulting from ART. Such efforts ultimately 
might lead ART patients and providers to view treatment 
success in terms of singleton pregnancies and births. In 
addition, continued research is needed to understand the 
adverse effects of ART on maternal and child health. CDC 
will continue to provide updates of ART use in the United 
States as data become available. 
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FIGURE 2. Percentage of transfers resulting in live births and 
singleton live births for assisted reproductive technology 
procedures performed among women who used freshly fertilized 
embryos from their own eggs, by patient’s age group — 
United States, 2005 
<35 35–37 38–40 41–42 >42 
n = 35,509 n = 18,533 n = 15,127 n = 6,414 n = 3,214 



















TABLE 1. Number and outcomes of assisted reproductive technology (ART), by procedure type — United States, 2005 
Transfers 
No. No. Transfers Transfers resulting in Total 
No. ART procedures procedures resulting in No. resulting in No. singleton no. 
ART procedure procedures progressing progressing No. pregnancies live-birth live births singleton live births live-born 
type started to retrievals to transfers pregnancies (%) deliveries (%) live births (%) infants 
Patient’s eggs used 
Freshly fertilized embryos 97,442 85,713 78,797 33,101 42.0 27,047 34.3 18,385 23.3 36,300 
Thawed embryos 20,657 NA* 18,812 6,721 35.7 5,275 28.0 4,076 21.7 6,563 
Donor eggs used 
Freshly fertilized embryos 10,620 9,989 9,649 5,877 60.9 5,043 52.3 2,984 30.9 7,190 
Thawed embryos 5,541 NA 4,997 1,952 39.1 1,545 30.9 1,127 22.6 1,988 
Total 134,260† NA 112,255 47,651 42.4 38,910 34.7 26,572 23.7 52,041 
* Not applicable. 
† This number does not include 358 ART procedures in which a new treatment procedure was being evaluated. 
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TABLE 2. Number of reported assisted reproductive technology (ART) procedures performed, number of pregnancies, number of 
live-birth deliveries, and number of infants born, by patient’s state/territory of residence* at time of treatment — United States, 2005 
Ratio of no. ARTProcedures started Transfers Pregnancies Live-birth deliveries Infants born procedures 
Patient's No. with No. with No. with No. with No. with started/ 
state/territory 













Alabama 736 0 600 0 291 0 244 0 338 0 161.5 
Alaska 150 0 132 0 62 0 47 0 63 0 226.0 
Arizona 2,117 83 1,788 73 728 28 585 21 767 26 356.4 
Arkansas 483 0 426 0 179 0 160 0 215 0 173.8 
California 18,655 1,856 16,151 1,584 6,495 587 5,278 485 7,159 637 516.3 
Colorado 1,810 52 1,568 50 860 32 731 31 999 46 388.0 
Connecticut 2,749 54 2,224 46 980 24 782 19 1,025 23 783.1 
Delaware 346 0 281 0 140 0 113 0 148 0 410.2 
District of Columbia§ 642 59 500 44 190 19 151 16 202 21 1,166.2 
Federated States of Micronesia ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ 
Florida 6,364 149 5,191 124 2,213 53 1,822 45 2,418 60 357.7 
Georgia 2,938 1,344 2,521 1,148 1,119 506 940 427 1,286 574 323.8 
Guam ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ 
Hawaii 849 3 702 3 244 1 193 1 264 2 665.8 
Idaho 399 0 361 0 187 0 172 0 241 0 279.2 
Illinois 9,449 41 7,673 33 3,030 14 2,438 12 3,211 16 740.3 
Indiana 1,854 4 1,540 4 580 3 488 2 669 2 295.6 
Iowa 839 0 681 0 370 0 312 0 414 0 282.8 
Kansas 625 1 507 1 245 0 196 0 271 0 227.7 
Kentucky 929 1 800 1 363 1 291 1 403 2 222.6 
Louisiana 751 1 585 1 253 0 222 0 301 0 166.0 
Maine 217 0 174 0 80 0 71 0 95 0 164.2 
Maryland 4,685 57 3,829 48 1,599 23 1,261 20 1,656 24 836.5 
Massachusetts 8,571 3,035 7,185 2,536 2,853 905 2,303 737 2,964 964 1,339.5 
Michigan 3,183 16 2,610 12 1,121 5 945 5 1,285 7 314.5 
Minnesota 1,864 6 1,665 6 833 3 717 3 971 3 363.2 
Mississippi 439 0 367 0 165 0 141 0 187 0 150.3 
Missouri 1,703 492 1,403 423 689 197 575 167 740 217 293.6 
Montana 165 0 138 0 66 0 56 0 79 0 176.3 
Nebraska 656 3 514 1 224 0 192 0 255 0 373.0 
Nevada 1,184 38 1,052 38 477 22 392 19 526 24 490.3 
New Hampshire 774 0 656 0 275 0 221 0 292 0 590.9 
New Jersey 9,325 465 7,466 383 3,205 159 2,586 124 3,459 169 1,069.6 
New Mexico 311 1 255 1 151 0 121 0 169 0 161.3 
New York 12,032 390 9,901 348 3,707 154 2,896 113 3,807 148 624.9 
New York City 4,681 1,706 3,737 1,387 1,555 596 1,234 468 1,604 610 569.9 
North Carolina 2,587 3 2,185 3 923 3 771 2 1,029 2 297.9 
North Dakota 204 0 188 0 74 0 66 0 84 0 320.4 
Ohio 3,361 41 2,870 36 1,185 10 1,002 9 1,365 11 293.2 
Oklahoma 569 2 495 2 264 2 219 1 288 2 160.4 
Oregon 1,010 5 879 5 460 5 382 4 533 8 277.4 
Pennsylvania 5,071 472 4,155 361 1,650 127 1,346 107 1,808 134 408.0 
Puerto Rico 422 23 358 20 148 5 109 0 148 0 107.9 
Rhode Island 833 2 699 1 290 0 244 0 331 0 774.0 
South Carolina 974 0 888 0 461 0 376 0 513 0 228.9 
South Dakota 176 0 154 0 64 0 56 0 74 0 226.8 
Tennessee 1,031 2 880 2 441 1 377 1 511 2 172.9 
Texas 6,582 109 5,611 99 2,764 47 2,245 37 3,103 51 287.9 
Utah 662 3 582 3 291 1 264 1 371 1 268.1 
Vermont 174 0 143 0 53 0 39 0 47 0 279.3 
Virgin Islands, U.S. 25 0 23 0 12 0 11 0 11 0 230.0 
Virginia 4,232 63 3,579 55 1,471 15 1,204 14 1,572 19 559.2 
Washington 1,668 28 1,459 24 726 10 612 8 811 9 265.3 
West Virginia 209 0 181 0 79 0 67 0 92 0 115.0 
Wisconsin 1,570 22 1,360 7 604 2 510 1 685 1 283.6 
Wyoming 71 0 64 0 33 0 29 0 39 0 139.4 
Non-U.S. resident 345 0 310 0 126 0 103 0 141 0 —** 
Total 134,260 10,632 112,255 8,913 47,651 3,560 38,910 2,901 52,041 3,815 453.0 
* In cases of missing residency data, the patient’s state of residency was assigned as the state in which the ART procedure was performed.
† Source of population size: July 1, 2005, state population estimates. Population Division, U.S. Census Bureau.
§ Of all ART procedures, 0.7% were reported from military medical centers located in California, District of Columbia, Hawaii, and Texas. States and territories for which >1% 
of ART procedures among state residents were performed in a military medical center were Alaska, Delaware, District of Columbia, Guam, Hawaii, Kansas, Maryland, New 
Mexico, North Carolina, Oklahoma, South Carolina, Texas, Virginia, and Wyoming. In District of Columbia, Guam, and Hawaii, >5% of ART procedures among residents were 
performed in a military medical center.
¶ Data not provided to preserve confidentiality but included in totals. 
** Non-U.S. residents excluded because the appropriate denominators were unknown. 
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TABLE 3. Percentage distribution of selected patient and treatment factors for assisted reproductive technology (ART) transfer 
procedures among patients who used freshly fertilized embryos from their own eggs, by patient’s age group — United States, 2005 
Patient age group (yrs) 
<35 35–37 38–40 41–42 >42 
(n = 35,509) (n = 18,533) (n = 15,127) (n = 6,414) (n = 3,214) 
Patient/Treatment factors (%) (%) (%) (%) (%) 
Patient factors 
Diagnosis 
Tubal factor 11.2 12.2 11.0 7.8 6.3 
Ovulatory dysfunction 9.2 5.4 3.2 2.5 1.7 
Diminished ovarian reserve 2.2 4.5 10.6 19.5 27.7 
Endometriosis 7.2 6.4 4.2 2.4 1.8 
Uterine factor 1.1 1.4 2.0 2.0 1.3 
Male factor 24.7 19.6 14.3 9.3 6.8 
Other causes 5.6 7.1 8.3 9.5 9.8 
Unexplained cause 12.0 14.6 13.3 11.3 8.9 
Multiple factors, female only 9.0 10.9 13.4 15.0 16.3 
Multiple factors, female and male 17.7 17.8 19.6 20.6 19.3 
No. previous ART procedures 
0 64.6 55.1 50.1 45.9 43.0 
>1 35.4 44.9 49.9 54.1 57.0 
No. previous births 
0 78.7 68.6 66.2 63.7 63.5 
>1 21.3 31.4 33.8 36.3 36.5 
Treatment factors 
Method of embryo fertilization and transfer* 
IVF-ET without ICSI 29.7 32.1 33.4 33.5 33.0 
IVF-ET with ICSI 70.0 67.7 66.2 66.0 66.2 
IVF-ET with ICSI among couples 
diagnosed with male factor infertility 39.4 34.4 30.6 26.4 22.8 
IVF-ET with ICSI among couples not 
diagnosed with male factor infertility 30.6 33.3 35.6 39.6 43.4 
GIFT 0.0 0.0 0.1 0.1 0.3 
ZIFT 0.2 0.2 0.2 0.3 0.3 
Combination 0.0 0.0 0.1 0.1 0.2 
No. of days of embryo culture† 
1 0.1 0.1 0.1 0.0 0.1 
2 0.2 0.2 0.3 0.4 0.4 
3 3.4 3.8 3.9 4.8 5.9 
4 62.6 67.3 72.3 74.3 77.4 
5 2.9 3.5 4.3 5.1 5.4 
6 28.3 22.9 17.4 13.9 9.8 
>7 2.3 2.0 1.6 1.3 0.9 
No. embryos transferred 
1 7.0 9.0 10.9 14.2 18.9 
2 58.8 41.0 25.2 19.9 20.0 
3 26.7 35.0 33.5 23.6 20.3 
4  5.8 11.7 21.6 21.8 17.3 
>5 1.8 3.3 8.7 20.5 23.5 
Extra embryo(s) available and cryopreserved 
Yes 55.0 67.0 80.5 89.8 95.5 
No 45.0 33.0 19.5 10.2 4.5 
Use of gestational carrier 
Yes 1.0 1.1 1.2 1.3 1.3 
No  99.0 98.9 98.8 98.7 98.7 
* IVF-ET = in vitro fertilization with transcervical embryo transfer; ICSI = intracytoplasmic sperm injection; GIFT = gamete intrafallopian transfer; ZIFT = zygote intrafallopian 
transfer; and Combination = a combination of IVF with or without ICSI and either GIFT or ZIFT. 
† In cases of GIFT, gametes were not cultured but were transferred on day 1. 
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TABLE 4. Percentages of transfers resulting in live births for assisted reproductive technology (ART) procedures performed 
among patients who used freshly fertilized embryos from their own eggs, by patient’s age group and selected patient and treatment 
factors — United States, 2005 
Transfers resulting in live births 
<35 yrs 35–37 yrs 38–40 yrs 41–42 yrs >42 yrs 
Patient/Treatment factors (%) (%) (%) (%) (%) 
Patient factors 
Diagnosis 
Tubal factor 43.1* 34.0 26.2* 16.0 4.9 
Ovulatory dysfunction 45.8 37.6 30.6 16.0 7.1 
Diminished ovarian reserve 40.3 30.4 23.2 13.1 5.5 
Endometriosis 44.2 36.9 27.1 18.5 1.8 
Uterine factor 35.9 38.5 22.1 16.5 2.4 
Male factor 44.3 38.0 28.1 16.1 8.6 
Other causes 43.2 35.6 23.1 13.1 6.0 
Unexplained cause 44.5 37.9 27.9 15.3 6.3 
Multiple factors, female only 41.1 34.3 23.6 17.2 6.7 
Multiple factors, female and male 41.9 35.1 24.1 13.8 5.0 
No. previous ART procedures 
0 45.6* 37.8* 27.2* 15.1 5.0 
>1 39.4 33.7 23.7 14.7 6.4 
No. previous births 
0 42.4* 35.0* 24.3* 13.9 5.0 
>1 46.8 38.0 27.6 16.6 7.2 
Treatment factors 
Method of embryo fertilization and transfer† 
IVF-ET without ICSI 46.1* 38.1* 28.2* 15.6 6.6 
IVF-ET with ICSI among couples diagnosed with 
male factor infertility 43.3 36.6 25.5 14.5 5.6 
IVF-ET with ICSI among couples not diagnosed 
with male factor infertility 40.9 33.2 22.8 14.7 5.4 
No. days of embryo culture§ 
3 40.9* 34.6* 24.1* 14.2* 5.2* 
5 50.5 41.8 33.5 21.0 11.1 
No. embryos transferred 
1 28.0* 17.8* 10.2* 5.9* 1.6* 
2 47.2 39.0 26.1 11.8 4.7 
3 40.8 37.5 27.2 16.4 6.3 
4 38.0 36.5 29.0 18.0 8.3 
>5 33.2 30.3 26.9 19.0 7.9 
Extra embryos available and cryopreserved 
Yes 37.1* 31.2* 22.5* 13.6* 5.3* 
No 51.1 45.7 37.4 26.7 16.0 
Use of gestational carrier 
Yes 43.3 35.9 25.4 14.9 5.9 
No 47.9 39.2 30.7 15.1 2.4 
Total transfers resulting in live births 43.4 36.0 25.4 14.9 5.8 
* p<0.05, chi-square to test for variations in live-birth rates across patient and treatment factor categories within each age group.
† IVF-ET = in vitro fertilization with transcervical embryo transfer, and ICSI = intracytoplasmic sperm injection. ART procedures including gamete intrafallopian transfer (GIFT), 
zygote intrafallopian transfer (ZIFT), and a combination of IVF with or without ICSI and either GIFT or ZIFT were not included because each of these accounted for a small 
proportion of procedures.
§ Limited to 3 and 5 days to embryo culture. ART procedures including 1, 2, 4, 6 and >7 days to embryo culture were not included because each of these accounted for a limited 
proportion of procedures. 
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TABLE 5. Multiple-birth risk, by type of assisted reproductive technology (ART) transfer procedure performed — United States, 2005 
No. Multiple-birth No. Infants born in 
Patient live-birth deliveries infants multiple-birth deliveries 
Procedure type age group (yrs) deliveries No. (%)* born No. (%) 
Patient’s eggs used 
Freshly fertilized embryos All ages 27,047 8,662 32.0 36,300 17,915 49.4 
<35 15,396 5,478 35.5 21,261 11,343 53.4 
35–37 6,662 2,056 30.8 8,854 4,248 47.9 
38–40 3,847 966 25.1 4,875 1,994 40.9 
41–42 955 138 14.4 1,099 282 25.7 
>42 187 24 12.8 211 48 22.7 
Thawed embryos All ages 5,275 1,199 22.7 6,563 2,487 37.9 
<35 3,035 740 24.4 3,835 1,540 40.2 
35–37 1,329 275 20.7 1,617 563 34.8 
38–40 676 143 21.1 832 299 36.0 
41–42 155 32 20.6 189 66 35.0 
>42 80 9 11.3 90 19 21.1 
Donor’s eggs used† 
Freshly fertilized embryos All ages 5,043 2,059 40.8 7,190 4,206 58.5 
Thawed embryos All ages 1,545 418 27.1 1,988 861 43.3 
Total All ages 38,910 12,338 31.7 52,041 25,469 48.9 
* Multiple-birth risk.
† Age-specific statistics are not presented for procedures that used donor eggs because only limited variation by age exists among these procedures. 
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TABLE 6. Percentages of transfers resulting in live births and percentages of singletons, twins, and triplets or higher-order 
multiples for assisted reproductive technology (ART) procedures that used freshly fertilized embryos from the patient’s own 
eggs, by patient’s age group, number of embryos transferred, and embryo availability — United States, 2005 
ART transfer procedures for women known 
All ART transfer procedures to have more embryos available than transferred 
Triplets Triplets 
Transfers or higher- Transfers or higher-
Patient age group resulting in order resulting in order 
(yrs)/No. embryos live births Singletons Twins multiples live births Singletons Twins multiples 
transferred No. (%) (%) (%) (%) No. (%) (%) (%) (%) 
<35 
1 2,477 28.0 98.6 1.4 0.0 712 43.3 98.1 1.9 0.0 
2 20,863 47.2 63.8 35.2 1.0 11,496 52.8 60.2 38.5 1.2 
3 9,485 40.8 60.9 32.8 6.3 3,166 47.5 55.5 36.0 8.5 
4 2,043 38.0 61.0 30.9 8.1 485 45.8 54.1 32.4 13.5 
>5 629 33.2 60.3 32.1 7.7 98 41.8 48.8 39.0 12.2 
35–37 
1 1,662 17.8 97.6 2.4 0.0 242 38.8 97.9 2.1 0.0 
2 7,592 39.0 71.1 28.4 0.4 3,366 47.4 66.7 32.7 0.6 
3 6,492 37.5 65.9 30.6 3.6 1,998 43.6 59.1 35.7 5.2 
4 2,175 36.5 63.1 31.8 5.2 427 47.1 59.2 34.3 6.5 
>5 603 30.3 60.7 31.1 8.2 86 38.4 57.6 30.3 12.1 
38–40 
1 1,652 10.2 97.0 3.0 0.0 67 35.8 95.8 4.2 0.0 
2 3,818 26.1 79.2 20.5 0.3 942 41.8 71.8 27.7 0.5 
3 5,065 27.2 75.1 23.0 1.9 1,203 33.6 69.8 27.5 2.7 
4 3,267 29.0 68.8 27.7 3.5 587 39.5 62.9 33.2 3.9 
>5 1,321 26.9 67.7 30.3 2.0 155 32.3 64.0 34.0 2.0 
41–42 
1 913 5.9 94.4 5.6 0.0 9 * * * * 
2 1,278 11.8 88.7 10.6 0.7 106 31.1 87.9 12.1 0.0 
3 1,511 16.4 85.9 14.1 0.0 188 30.9 79.3 20.7 0.0 
4 1,397 18.0 87.3 11.1 1.6 199 22.6 82.2 13.3 4.4 
>5 1,313 19.0 79.6 18.8 1.6 150 24.0 63.9 27.8 8.3
 >42 
1 608 1.6 100.0 0.0 0.0 7 * * * * 
2 644 4.7 93.3 6.7 0.0 13 30.8 50.0 50.0 0.0 
3 651 6.3 85.4 14.6 0.0 34 17.6 66.7 33.3 0.0 
4 555 8.3 91.3 6.5 2.2 42 14.3 83.3 16.7 0.0 
>5 755 7.9 80.0 20.0 0.0 48 12.5 83.3 16.7 0.0 
* Statistics not provided for cases in which the denominator is <10. 
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TABLE 7. Percentage of transfers resulting in live births and multiple-birth risk for assisted reproductive technology (ART) procedures 
using freshly fertilized embryos from the patient's own eggs, by patient's age group, number of embryos transferred, day of embryo 
transfer, and embryo availability — United States, 2005 
Day 3  Day 5 
ART transfer procedures 
for women known to have 
ART transfer procedures 
for women known to have 
more embryos available more embryos available 
All ART transfer procedures than transferred All ART transfer procedures than transferred 
Transfers Multiple- Transfers Multiple- Transfers Multiple- Transfers Multiple-
resulting in birth resulting in birth resulting in birth resulting in birth 
Patient age 
group (yrs) No. 
live births deliveries 
(%) (%) No. 
live births deliveries 
(%) (%) No. 
live births deliveries 
(%) (%) No. 
live births deliveries 
(%) (%) 
<35 
1 1,324 22.2 0.3 221 34.8 0.0 812 39.4 2.8 446 48.2 2.8 
2 11,291 43.5 32.0 5,807 49.2 36.0 7,814 53.6 41.5 4,881 57.5 43.7 
3 7,463 41.2 39.1 2,511 48.3 44.2 1,178 39.9 40.4 377 43.5 48.8 
4 1,653 38.7 39.7 390 46.7 44.5 179 37.4 37.3 50 44.0 54.5 
>5 495 33.5 41.0 73 45.2 51.5 56 42.9 33.3 5 * * 
35–37 
1 999 13.8 2.9 76 27.6 4.8 385 30.6 0.8 141 48.2 1.5 
2 4,024 35.2 24.2 1,515 44.4 29.1 2,872 45.5 33.5 1,649 50.3 36.5 
3 5,098 37.4 32.9 1,573 42.8 39.2 820 38.2 45.0 247 44.9 55.0 
4 1,851 37.1 36.5 363 48.5 39.8 135 25.2 38.2 26 34.6 22.2 
>5 496 32.7 39.5 73 41.1 43.3 39 15.4 50.0 7 * * 
38–40 
1 1,061 7.8 3.6 20 20.0 0.0 308 17.9 3.6 37 48.6 5.6 
2 2,098 19.3 14.3 289 34.3 23.2 1,242 38.2 27.2 579 45.9 31.2 
3 3,859 26.3 24.2 897 32.0 30.0 790 34.3 28.8 226 40.7 31.5 
4 2,781 29.2 31.5 514 39.3 37.6 223 30.0 28.4 43 46.5 35.0 
>5 1,138 28.2 33.3 134 34.3 39.1 69 21.7 33.3 7 * * 
41–42 
1 572 3.7 0.0 0 * * 178 12.4 9.1 9 * * 
2 794 9.1 8.3 18 33.3 0.0 279 20.1 8.9 76 34.2 11.5 
3 1,081 14.6 12.0 119 31.9 13.2 261 25.3 21.2 52 32.7 35.3 
4 1,169 18.1 11.3 175 22.3 17.9 116 20.7 25.0 16 31.3 20.0 
>5 1,146 18.4 18.5 133 22.6 30.0 57 33.3 31.6 7 * * 
>42 
1 412 1.0 0.0 3 * * 90 3.3 0.0 2 * * 
2 469 2.8 7.7 6 * * 75 16.0 8.3 5 * * 
3 502 5.4 11.1 23 13.0 33.3 61 13.1 25.0 9 * * 
4 445 8.8 7.7 33 18.2 16.7 56 12.5 14.3 6 * * 
>5 660 7.0 15.2 42 9.5 0.0 32 15.6 60.0 3 * * 
*Statistics are not provided in cases in which the denominator is <10. 
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TABLE 8. Number and percentage of infants born in multiple-birth deliveries, by patient's state/territory of residence* at time of 
assisted reproductive technology (ART) procedure — United States, 2005 
No. infants born in 
No. infants born multiple-birth deliveries Infant born in Infants born in 
Patient’s state 










Infants born in 
twin deliveries 
(%) 
triplet or higher-order 
deliveries 
(%) 
Alabama 338 0 181 0 53.6 44.2 2.6 
Alaska 63 0 32 0 50.8 39.0 12.7 
Arizona 767 26 347 10 45.2 51.2 4.9 
Arkansas 215 0 109 0 50.7 42.3 4.1 
California 7,159 637 3,635 294 50.8 45.8 5.0 
Colorado 999 46 525 30 52.6 48.5 1.5 
Connecticut 1,025 23 480 8 46.8 44.2 5.3 
Delaware 148 0 69 0 46.6 49.8 2.7 
District of Columbia§ 202 21 101 10 50.0 42.8 4.8 
Federated States of Micronesia ¶ ¶ ¶ ¶ ¶ ¶ ¶ 
Florida 2,418 60 1,160 29 48.0 41.9 4.5 
Georgia 1,286 574 663 282 51.6 43.6 8.0 
Guam ¶ ¶ ¶ ¶ ¶ ¶ ¶ 
Hawaii 264 2 136 2 51.5 42.1 4.6 
Idaho 241 0 131 0 54.4 44.5 6.3 
Illinois 3,211 16 1,501 8 46.7 45.9 6.1 
Indiana 669 2 347 0 51.9 0.0 0.0 
Iowa 414 0 197 0 47.6 32.1 8.3 
Kansas 271 0 145 0 53.5 44.6 2.0 
Kentucky 403 2 208 2 51.6 45.6 8.7 
Louisiana 301 0 153 0 50.8 46.3 3.2 
Maine 95 0 47 0 49.5 46.4 3.4 
Maryland 1,656 24 769 8 46.4 43.3 7.6 
Massachusetts 2,964 964 1,293 440 43.6 27.7 6.4 
Michigan 1,285 7 650 4 50.6 40.6 3.0 
Minnesota 971 3 500 0 51.5 43.6 8.2 
Mississippi 187 0 89 0 47.6 41.5 8.9 
Missouri 740 217 318 100 43.0 0.0 0.0 
Montana 79 0 44 0 55.7 46.5 4.2 
Nebraska 255 0 121 0 47.5 53.3 2.6 
Nevada 526 24 262 10 49.8 46.8 8.9 
New Hampshire 292 0 139 0 47.6 46.9 1.0 
New Jersey 3,459 169 1,692 89 48.9 44.5 3.1 
New Mexico 169 0 95 0 56.2 48.5 5.0 
New York 3,807 148 1,768 68 46.4 50.0 0.0 
New York City 1,604 610 729 276 45.4 46.0 5.1 
North Carolina 1,029 2 498 0 48.4 54.4 1.8 
North Dakota 84 0 34 0 40.5 40.7 4.6 
Ohio 1,365 11 688 4 50.4 43.5 7.1 
Oklahoma 288 2 138 2 47.9 42.8 2.6 
Oregon 533 8 298 8 55.9 38.5 6.8 
Pennsylvania 1,808 134 896 54 49.6 41.6 5.9 
Puerto Rico 148 0 77 0 52.0 44.6 7.0 
Rhode Island 331 0 174 0 52.6 0.0 0.0 
South Carolina 513 0 261 0 50.9 48.0 5.5 
South Dakota 74 0 37 0 50.0 37.3 5.7 
Tennessee 511 2 261 2 51.1 42.5 5.1 
Texas 3,103 51 1,666 27 53.7 49.2 3.3 
Utah 371 1 208 0 56.1 50.8 0.0 
Vermont 47 0 16 0 34.0 43.5 4.2 
Virgin Islands, U.S. 11 0 0 0 0.0 41.0 7.7 
Virginia 1,572 19 713 10 45.4 48.3 5.4 
Washington 811 9 387 2 47.7 43.3 5.1 
West Virginia 92 0 48 0 52.2 43.2 4.8 
Wisconsin 685 1 344 0 50.2 48.4 3.1 
Wyoming 39 0 19 0 48.7 43.9 5.1 
Non-U.S. resident 141 0 70 0 49.6 36.9 12.8 
Total 52,041 3,815 25,469 1,779 48.9 43.9 5.1 
* In cases of missing residency data, the patient's place of residency was assigned as that in which the ART procedure was performed.
† Statistics might not sum to total because of rounding.
§ Of all ART procedures, 0.7% were reported from military medical centers located in California, District of Columbia, Hawaii, and Texas. States and territories for which >1% 
of ART procedures among state residents were performed in a military medical center were Alaska, Delaware, District of Columbia, Guam, Hawaii, Kansas, Maryland, New 
Mexico, North Carolina, Oklahoma, South Carolina, Texas, Virginia, and Wyoming. In District of Columbia, Guam, and Hawaii, >5% of ART procedures among residents were 
performed in a military medical center.
¶ Data not provided to preserve confidentiality but included in total. 
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TABLE 9. Contribution of assisted reproductive technology (ART) to the total number of live-born infants in the United States, by plurality 
— United States, 2005 
ART infants*†  U.S.-born infants§ 
Contribution 
of ART to total no. 
Plurality No. % of total No. % of total U.S.-born infants (%) 
Infants born in singleton deliveries 2,5143 (51.0) 3,998,533 (96.60 0.6 
Infants born in multiple-birth deliveries 2,4165 (49.0) 139,816 (3.40 17.3 
Twins 2,1598 (43.8) 133,122 (3.20 16.2 
Triplets or higher order 2,567 (5.2) 6,694 (0.20 38.3 
Total no. infants 49,308 4,138,349 1.2 
* Source: Assisted Reproductive Technology Surveillance System.
† Includes infants conceived from ART procedures performed in 2004 and born in 2005 and infants conceived from ART procedures performed in 2005 and born in 2005. 
§ Source: U.S. natality file, CDC, National Center for Health Statistics. 
TABLE 10. Percentage of adverse perinatal outcomes* among assisted reproductive technology (ART) infants† born in 2005, by 
plurality — United States, 2005 
LBW VLBW Preterm Preterm LBW Term LBW 
Plurality (%) (%) (%) (%) (%) 
ART singletons (n = 25,143) 9.4 1.8 14.9 7.1 2.3 
ART twins (n = 21,598) 57.1 8.7 66.3 48.2 8.8 
ART triplets or higher-order multiples (n = 2,567) 94.6 31.2 97.1 92.8 1.9 
* LBW = low birthweight (<2,500 g); VLBW = very low birthweight (<1,500 g); preterm = gestational age <37 weeks; preterm LBW = gestational age <37 weeks and low birthweight 
(<2,500 g); and term LBW = gestational age >37 weeks and low birthweight (<2,500 g). 
† Includes infants conceived from ART procedures performed in 2004 and born in 2005 and infants conceived from ART procedures performed in 2005 and born in 2005. 
Samples for calculations of percentages of outcomes were reduced from totals because of missing values for birthweight and gestational age. 
TABLE 11. Adverse perinatal outcomes* among assisted reproductive technology (ART) singleton infants born in 2005, by 
procedure type and selected maternal factors — United States† 
LBW VLBW Preterm Preterm LBW Term LBW 
Procedure/Maternal factor (%) (%) (%) (%) (%) 
Freshly fertilized embryos, patient eggs (n = 17,642) 9.5§ 1.7 13.4§ 6.9 2.7§ 
Maternal age group (yrs) 
<35 9.2 1.7 13.0 6.5 2.7 
35–37 9.9 1.8 14.0 7.5 2.4 
38–40 9.4 1.9 13.1 6.5 2.8 
41–42 11.6 2.3 15.8 8.7 3.0 
>42 7.5 0.7 11.8 4.1 3.4 
No. previous births 
0  10.2¶ 1.9 13.5 7.2 3.1¶ 
1 7.3 1.3 12.7 5.9 2.0 
>2 8.9 1.7 14.6 7.0 1.5 
Freshly fertilized embryos, donor’s eggs (n = 2,864) 11.0 2.0 16.9 9.0 2.1 
Thawed embryos** (n = 4,637) 7.9 1.7 19.5 6.8 1.1 
* LBW = low birthweight (<2,500 g); VLBW = very low birthweight (<1,500 g); preterm = gestational age <37 weeks; preterm LBW = gestational age <37 weeks and low birthweight 
(<2,500 g); and term LBW = gestational age >37 weeks and low birthweight (<2,500 g). 
† Includes infants conceived from ART procedures performed in 2004 and born in 2005 and infants conceived from ART procedures performed in 2005 and born in 2005. Analysis 
excludes 542 singletons (416 for missing birth weight, 113 for missing gestational age, and 13 for missing both).

§ p<0.01; chi-square to test for variations in adverse perinatal outcomes across procedure types.
 
¶ p<0.01; chi-square to test for variations in adverse perinatal outcomes across maternal factor categories.
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Abstract 
Problem/Condition: Malaria in humans is caused by intraerythrocytic protozoa of the genus Plasmodium (i.e., 
P. falciparum, P. vivax, P. ovale, and P. malariae). These parasites are transmitted by the bite of an infective female 
Anopheles species mosquito. The majority of malaria infections in the United States occur among persons who 
have traveled to areas with ongoing malaria transmission. In the United States, cases can occur through exposure 
to infected blood products, congenital transmission, or local mosquitoborne transmission. Malaria surveillance is 
conducted to identify episodes of local transmission and to guide prevention recommendations for travelers. 
Period Covered: This report summarizes cases in persons with onset of illness in 2006 and summarizes trends 
during previous years. 
Description of System: Malaria cases confirmed by blood film or polymerase chain reaction (PCR) are mandated 
to be reported to local and state health departments by health-care providers or laboratory staff members. Case 
investigations are conducted by local and state health departments, and reports are transmitted to CDC through 
the National Malaria Surveillance System (NMSS), National Notifiable Diseases Surveillance System (NNDSS), 
and direct CDC consultations. Data from these reporting systems serve as the basis for this report. 
Results: CDC received reports of 1,564 cases of malaria among persons in the United States with onset of symp­
toms in 2006, six of which were fatal. This is an increase of 2.4% from the 1,528 cases reported for 2005. 
P. falciparum, P. vivax, P. malariae, and P. ovale were identified in 39.2%, 17.6%, 2.9%, and 3.0% of cases, 
respectively. Ten patients (0.6%) were infected by two or more species. The infecting species was unreported or 
undetermined in 36.6% of cases. Compared with 2005, the largest increases in cases were from Asia (16.0%). 
Based on estimated volume of travel, the highest estimated relative case rates of malaria among travelers occurred 
among those returning from West Africa. Of 602 U.S. civilians who acquired malaria abroad and for whom 
chemoprophylaxis information was known, 405 (67.3%) reported that they had not followed a chemoprophylac­
tic drug regimen recommended by CDC for the area to which they had traveled. Seventeen cases were reported in 
pregnant women, among whom only one reported taking chemoprophylaxis precautions. Six deaths were reported; 
five of the persons were infected with P. falciparum and one with P. malariae. 
Interpretation: Despite the 2.4% increase in cases from 2005 to 2006, the numbers of malaria cases remained 
relatively stable during 2001–2006. No change was detected in the proportion of cases by species responsible for 
infection. U.S. civilians traveling to West Africa had the highest estimated relative case rates. In the majority of 
reported cases, U.S. civilians who acquired infection abroad had not adhered to a chemoprophylaxis regimen that 
was appropriate for the country in which they acquired malaria. 
Public Health Actions: Additional investigations were conducted of the six fatal cases that occurred in the United 
States. Persons traveling to a malarious area should take one of the recommended chemoprophylaxis regimens 
appropriate for the region of travel and use personal protection measures to prevent mosquito bites. Any person 
who has been to a malarious area and who subsequently has a fever or influenza-like symptoms should seek 
medical care immediately and report their travel history 
to the clinician; investigation should always include 
blood-film tests for malaria, with results made availableCorresponding author: Sonja Mali, MPH, Division of Parasitic Diseases,
 
National Center for Zoonotic, Vector-Borne, and Enteric Diseases, CDC, immediately. Malaria infections can be fatal if not diag­
4770 Buford Hwy., N.E., MS F-22, Atlanta, GA 30341. Telephone:
 nosed and treated promptly. CDC recommendations con­770-488-7757; Fax: 770-488-4465; E-mail: smali@cdc.gov. 
cerning malaria prevention are available at http://wwwn. 
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cdc.gov/travel/contentdiseases.aspx#malaria or by calling the CDC Malaria Branch on weekdays (telephone: 
770-488-7788; Monday–Friday, 8:00 A.M.–4:30 P.M. EST); during evenings, weekends, and holidays, call the 
CDC Director’s Emergency Operations Center (telephone: 770-488-7100), and ask to page the person on call 
for the Malaria Branch. Recommendations concerning malaria treatment are available at http://www.cdc.gov/ 
malaria/diagnosis_treatment/treatment.htm or by calling the CDC Malaria Hotline. 
Introduction 
Malaria in humans is caused by infection with one or 
more species of Plasmodium (i.e., P. falciparum, P. vivax, 
P. ovale, and P. malariae) that can infect humans. The infec­
tion is transmitted by the bite of an infective female 
Anopheles species mosquito. Malaria remains a devastating 
global problem, with an estimated 350–500 million cases 
and 1 million deaths occurring annually, 80% of them in 
sub-Saharan Africa (1). Forty-nine percent of the world’s 
population lives in areas where malaria is transmitted (e.g., 
109 countries in parts of Africa, Asia, the Middle East, 
Eastern Europe, Central America and South America, the 
Caribbean, and Oceania) (1). Before the 1950s, malaria 
was endemic throughout the southeastern United States; 
an estimated 600,000 cases occurred in 1914 (2). During 
the late 1940s, a combination of improved housing and 
socioeconomic conditions, water management, vector-
control efforts, and case management interrupted malaria 
transmission in the United States. Since then, malaria case 
surveillance has been maintained to detect locally acquired 
cases that could indicate the reintroduction of transmis­
sion and to monitor patterns of resistance to antimalarial 
drugs. Anopheline mosquitoes remain seasonally present 
in all states and territories except Hawaii. 
The majority of reported cases of malaria diagnosed each 
year in the United States are imported from regions where 
malaria transmission is known to occur, although congeni­
tal infections and infections resulting from exposure to blood 
or blood products are also reported in the United States. In 
addition, occasionally a limited number of cases are reported 
that might have been acquired through local mosquitoborne 
transmission (3). 
State and local health departments and CDC investigate 
malaria cases acquired in the United States, and CDC ana­
lyzes data from imported cases to detect trends in acquisi­
tion. This information is used to guide malaria prevention 
recommendations for international travelers. 
The signs and symptoms of malaria illness vary, but the 
majority of patients have fever. Other common symptoms 
include headache, back pain, chills, increased sweating, 
myalgia, nausea, vomiting, diarrhea, and cough. The diag­
nosis of malaria should always be considered for persons 
with these symptoms who have traveled to an area with 
known malaria transmission. Malaria also should be con­
sidered in the differential diagnosis of persons who have 
fever of unknown origin, regardless of their travel history. 
Untreated P. falciparum infections can rapidly progress to 
coma, renal failure, pulmonary edema, and death. This 
report summarizes malaria cases reported to CDC among 
persons with onset of symptoms in 2006. 
Methods 
Data Sources 
Malaria case data are reported to the National Malaria 
Surveillance System (NMSS) and the National Notifiable 
Diseases Surveillance System (NNDSS) (4). Although both 
systems rely on passive reporting, the numbers of reported 
cases might differ because of differences in collection and 
transmission of data. A substantial difference between the 
data collected in these two systems is that NMSS receives 
more detailed clinical and epidemiologic data regarding each 
case (e.g., information concerning the area to which the 
infected person has traveled). Malaria cases can be reported 
to CDC through NMSS, NNDSS, or direct consultation 
with CDC; therefore, cases identified through these vari­
ous paths are compared and compiled, duplicates are elimi­
nated, and cases are analyzed. This report presents data on 
the aggregate of cases reported to CDC through all report­
ing systems. 
Malaria cases confirmed by blood film or polymerase 
chain reaction (PCR) among civilians and military person­
nel are identified by health-care providers or laboratories. 
Each confirmed malaria case is reported to local or state 
health departments and to CDC on a uniform case-report 
form that contains clinical, laboratory, and epidemiologic 
information.* CDC reviews all report forms received and 
requests additional information from the provider or the 
state, if necessary (e.g., when no recent travel to a malari­
ous country is reported). Other cases are reported by tele­
phone to CDC directly by health-care providers, usually 
when they are seeking assistance with diagnosis or treat­
ment. Information regarding cases reported directly to CDC 
is shared with the relevant state health department. All cases 
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that have been reported as acquired in the United States 
are investigated further, including all induced and congeni­
tal cases and possible introduced or cryptic cases. Informa­
tion derived from uniform case-report forms is entered into 
a database and analyzed annually. 
A case rate for each country was estimated using esti­
mates of travel volume for U.S. travelers to each country 
where cases of malaria were acquired and the number of 
cases among U.S. travelers attributable to each country. 
Data used to estimate country-specific relative case rates 
were extrapolated from World Tourism Organization esti­
mates of annual numbers of U.S. travelers to specified coun­
tries (5). Estimated relative case rates were determined by 
dividing the individual country-specific case rate by the 
median individual country-specific case rate. 
Definitions 
The following definitions are used in this report: 
•	 U.S. residents: Persons living in the United States, 
including civilians and U.S. military personnel, regard­
less of legal citizenship. 
•	 Foreign residents: Persons who do not meet the defi­
nition of U.S. residents. 
•	 U.S. civilians: U.S. residents, excluding U.S. military 
personnel. 
•	 Laboratory criteria for diagnosis: Demonstration of 
malaria parasites on blood film or by PCR. 
•	 Confirmed case: Symptomatic or asymptomatic infec­
tion that occurs in a person in the United States or one 
of its territories who has laboratory-confirmed (by 
microscopy or PCR) malaria parasitemia, regardless of 
whether the person has had previous episodes of 
malaria while in other countries. A subsequent episode 
of malaria is counted as an additional case if the indi­
cated Plasmodium species differs from the initially iden­
tified species. A subsequent episode of malaria occurring 
in a person while in the United States could indicate a 
relapsing infection or treatment failure resulting from 
drug resistance if the indicated Plasmodium species is 
the same species identified previously. 
This report also uses terminology from recommendations 
of the World Health Organization (6). Definitions of the 
following terms are included for reference: 
•	 Autochthonous malaria: 
— Indigenous. Mosquitoborne transmission of malaria 
in a geographic area where malaria occurs regularly. 
— Introduced. Mosquitoborne transmission of malaria 
from a person with an imported case in an area where 
malaria does not occur regularly. 
•	 Imported malaria: Malaria acquired outside a specific 
area. In this report, imported cases are those acquired 
outside the United States and its territories. 
•	 Induced malaria: Malaria acquired through artificial 
means (e.g., blood transfusion or by using shared com­
mon syringes). 
•	 Relapsing malaria: Recurrence of disease after it has 
been apparently cured. In malaria, true relapses are 
caused by reactivation of dormant liver-stage parasites 
(hypnozoites) found in P. vivax and P. ovale. 
•	 Cryptic malaria: A case of malaria for which epide­
miologic investigations fail to identify a plausible mode 
of acquisition. (Cryptic malaria cases are primarily iden­
tified in countries where malaria is not endemic.) 
Laboratory Diagnosis 
Early and prompt diagnosis of malaria requires that phy­
sicians obtain a travel history from every febrile patient. 
Malaria should be included in the differential diagnosis of 
every febrile patient who has traveled to a malarious area. If 
malaria is suspected, a Giemsa-stained film of the patient’s 
peripheral blood should be examined for parasites as soon 
as possible. Thick and thin blood films must be prepared 
correctly because diagnostic accuracy depends on blood-
film quality and examination of the film by experienced 
laboratory personnel (7).† Certain reference laboratories and 
health departments have the capacity to perform PCR 
diagnosis of malaria, although PCR diagnosis generally is 
reserved for cases for which blood-film diagnosis of malaria 
or species determination is inadequate. 
Results 
General Surveillance 
For 2006, CDC received 1,564 reports of cases of 
malaria occurring among persons in the United States and 
its territories, representing a 2.4% increase from the 1,528 
cases reported with a date of onset in 2005 (7). A total of 
713 cases occurred among U.S. residents, and 217 cases 
occurred among foreign residents; resident status was not 
known for 634 cases. The number of cases increased 
during 1980–2000 among U.S. residents; however, dur­
ing 2001–2006, the number of cases plateaued (Table 1). 
† To obtain confirmatory diagnosis of blood films from questionable cases 
and to obtain appropriate treatment recommendations, contact either the 
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Plasmodium Species 
Of the 1,564 cases reported in 2006, the infecting 
Plasmodium species was identified and reported in only 991 
(63.4%) cases. P. falciparum and P. vivax make up the 
majority of infections and were identified in 61.8% and 
27.7% of infected persons of known species infection, 
respectively. The number of reported cases of P. falciparum 
and P. vivax remained relatively stable during 2004–2006 
(Table 2). Among 909 cases for which both the region of 
acquisition and the infecting species were known, 
P. falciparum accounted for 65.8% of infections acquired 
in Africa, 22.5% in the Americas, 9.3% in Asia, and 4.5% 
in Oceania (Table 3). Infections attributed to P. vivax 
accounted for 4.3% acquired in Africa, 58.3% in the Ameri­
cas, 61.5% in Asia, and 72.7% in Oceania. 
Region of Acquisition and Diagnosis 
All cases were reported as imported cases. Of 1,140 
imported cases for which the region of acquisition was 
known, 793 (69.6%) were acquired in Africa, 205 (18.0%) 
in Asia, 120 (10.5%) in the Americas, and 22 (1.9%) in 
Oceania (Table 3). West Africa accounted for 563 (71.0%) 
cases acquired in Africa, and India accounted for 121 
(59.0%) cases acquired in Asia. In the Americas, a com­
bined total of 82 (68.3%) cases were acquired in Central 
America and the Caribbean (The Bahamas, Belize, Costa 
Rica, Dominican Republic, El Salvador, Guatemala, Haiti, 
Honduras, Jamaica, and Nicaragua), followed by 27 
(22.5%) cases in South America (Bolivia, Brazil, Ecuador, 
Guyana, Peru, and Suriname) and 11 (9.2%) cases in 
Mexico. Information regarding region of acquisition was 
missing for 424 (27.7%) imported cases. Among U.S. 
civilians, a small but steady increase (16%) in cases ac­
quired in Asia occurred from 2005 to 2006. 
In the United States, six state health departments 
accounted for 47.8% of the reported cases: California 
(n = 185), New York City (n = 174), Texas (n = 129), 
Georgia (n = 90), New Jersey (n = 87), and Illinois 
(n = 82) (Figure 1). Compared with 2005, the states with 
the most significant change in number of reported malaria 
cases in 2006 were Georgia and Alaska. The number of 
cases reported in Georgia increased from 54 cases in 2005 
to 90 cases in 2006, and Alaska reported an increase from 
eight cases in 2005 to 23 cases in 2006; all cases occurred 
among U.S. military personnel, all of whom had traveled 
to Afghanistan. 
Imported Malaria by Resident Status 
Of 930 imported malaria cases of known resident status, 
713 (76.7%) occurred among U.S. residents, and 217 
(23.3%) occurred among residents of other countries. Of 
the 713 imported cases, 511 (71.7%) were acquired in 
Africa, 116 (16.3%) were acquired in Asia, and 42 (5.9%) 
were acquired in Central America and the Caribbean 
(Table 4). Of the 217 imported cases among foreign resi­
dents, 131 (60.4%) were acquired in Africa. Of patients 
with foreign cases for whom purpose of travel was known, 
76 (58%) identified as being a recent immigrant or refu­
gee, and 22 (17%) reported visiting friends and relatives in 
the United States. 
Relative Case Rates Among 
U.S. Residents 
In 2006, the countries with the lowest estimated case 
rates of malaria among U.S. travelers (among countries that 
reported cases) were The Bahamas and Jamaica, both of 
which had been considered nonendemic countries but 
experienced malaria outbreaks in 2006 (Figure 2). Examples 
of other countries with low estimated relative case rates 
include Mexico, Vietnam, Costa Rica, and Thailand. For 
many of these countries, malaria risk areas are concentrated 
in small parts of the country. Examples of countries with 
estimated relative case rates in the middle range include 
India, Honduras, Haiti, and Kenya, which have malaria 
transmission occurring more homogenously throughout the 
country. Estimated relative case rates were highest in coun­
tries in West Africa and Oceania, including Nigeria, Ghana, 
Papua New Guinea, and Vanuatu. These high estimated 
case rates not only reflect widespread transmission areas 
but also likely reflect higher transmission intensity. 
Interval Between Arrival and Illness 
Both the interval between date of arrival in the United 
States and onset of illness and the infecting Plasmodium 
species were known for only 622 (39.8%) of the imported 
malaria cases (Table 5). Symptoms began before arrival in 
the United States for 40 (6.4%) persons and after arrival 
for 582 (93.6%) persons. Clinical malaria occurred <30 days 
after arrival in 384 (89.5%) of the 429 persons with 
P. falciparum cases and in 69 (54.3%) of the 127 P. vivax 
cases (Table 5). Six (1.0%) of 622 persons became ill with 
an infection with P. vivax or P ovale >1 year after returning 
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Imported Malaria Among U.S. Military 
Personnel 
In 2006, 50 cases of imported malaria were reported 
among U.S. military personnel. Information on infecting 
species was known for 38 cases: 33 cases of P. vivax, four 
cases of P. falciparum, and one case of P. malariae. Among 
the 38 cases with known infecting species, 33 patients had 
reported taking chemoprophylaxis, of whom 19 (57.5%) 
had taken the correct CDC-recommended antimalarial drug 
for the specific region of travel; only one patient reported 
adherence to the prescribed drug regimen. These cases were 
reported by state health departments and do not include 
all cases reported through malaria surveillance activities 
conducted by the U.S. Department of Defense. 
Chemoprophylaxis Use Among 
U.S. Civilians 
Information concerning chemoprophylaxis use and travel 
area was known for 602 (90.8%) of the 663 U.S. civilians 
who had imported malaria. Of these 602 patients, 405 
(67.3%) had not taken any chemoprophylaxis. Of the 197 
patients who did report taking malaria chemoprophylaxis, 
58 (29.4%) had not taken a CDC-recommended drug for 
the area visited, whereas 131 (20.9%) had taken a CDC-
recommended drug (7). Data for the specific drug taken 
were missing for the remaining eight (4.1%) travelers. A 
total of 58 (44.3%) patients receiving CDC-recommended 
chemoprophylaxis reported taking mefloquine; 36 (27.5%) 
had taken doxycycline; 25 (19.1%) had taken atovaquone­
proguanil; and eight (6.1%) who had traveled only in 
areas where chloroquine-resistant malaria has not been docu­
mented had taken chloroquine. Of the 131 persons taking 
a CDC-recommended malaria chemoprophylaxis for the 
travel region, only 52 (40.0%) reported adherence to the 
prescribed drug regimen. 
Malaria Infection After Recommended 
Prophylaxis Use 
A total of 220 patients (including 136 U.S. civilians, 41 
persons in the U.S. military, eight foreign residents, and 
35 persons for whom information regarding status was 
missing) contracted malaria after taking a recommended 
antimalarial drug for chemoprophylaxis. Of these, 76 
(34.5%) reported complete adherence with the drug regi­
men, and 104 (47.3%) reported nonadherence; adherence 
was unknown for the remaining 40 (18.2%). Information 
regarding infecting species was available for 178 (80.9%) 
patients who had taken a recommended antimalarial drug; 
the infecting species was undetermined for the remaining 
42 patients. 
Cases Caused by P. vivax or P. ovale 
Among the 220 patients who received a diagnosis of 
malaria after recommended chemoprophylaxis use, 70 
(31.8%) had cases that were caused by P. vivax, and 10 
(4.5%) had cases caused by P. ovale. Among the 80 total 
cases of P. vivax or P. ovale, 41 (51.2%) occurred >45 days 
after arrival in the United States. These cases were consis­
tent with relapsing infections and do not indicate primary 
prophylaxis failures. Information on 19 cases was insuffi­
cient (i.e., missing data regarding symptom onset or 
return date) to assess whether the infection was a relapse 
infection. A total of 20 cases occurred <45 days after the 
patient returned to the United States; 10 each caused by 
P. vivax and P. ovale. Nine of the 20 patients did not adhere 
to their malaria chemoprophylaxis regimen; information 
regarding drug regimen adherence was missing for four cases. 
Seven patients reported adherence with an antimalarial 
chemoprophylaxis regimen. Of these seven, three patients 
had traveled to Africa, two of whom reported taking 
atovaquone-proguanil as malaria chemoprophylaxis and one 
who reported taking doxycycline. Two patients had trav­
eled to Asia; one had traveled to India and had taken pri­
maquine, and one had traveled to Iraq and taken mefloquine 
for chemoprophylaxis. The remaining two patients had trav­
eled to Central America and South America; one patient 
had traveled to Peru and took doxycycline, and one had 
traveled to Honduras and taken mefloquine for chemopro­
phylaxis. Possible explanations for these cases include 
inappropriate dosing, unreported nonadherence to the regi­
men, malabsorption of the drug, or emerging parasite 
resistance. 
Cases Caused by P. falciparum 
and P. malariae 
Ninety-four cases of malaria were reported among per­
sons who had taken a recommended antimalarial drug for 
chemoprophylaxis, including 78 cases of P. falciparum and 
16 of P. malariae. Of the 78 P. falciparum cases among those 
who reported taking a recommended antimalarial drug, all 
except one case was acquired in Africa. Forty-three (55.1%) 
patients reported nonadherence to the antimalarial drug 
regimen; adherence information was not available for 14 
cases. In 21 (26.9%) cases, patients reported adherence 
with malaria chemoprophylaxis, all of whom had traveled 
to Africa. Fourteen patients reported taking mefloquine, 
three doxycycline, one primaquine, and three took 
atovaquone-proguanil. Of the 16 P. malariae cases, 11 were 
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acquired in Africa, four in Asia, and one in the Caribbean. 
Five patients reported nonadherence to the antimalarial drug 
regimen, and no adherence information was available for 
five cases. For the remaining six cases, patients reported 
adhering to the drug regimen; three took mefloquine, two 
took doxycycline, and one took atovaquone-proguanil. 
Cases of Mixed-Species Infection 
Among the 220 patients who had taken a recommended 
malaria chemoprophylaxis, four had a mixed Plasmodium 
species infection. Three patients had traveled to Africa, two 
of whom had a mixed infection of P. vivax and P. falciparum, 
and one who had P. vivax and P. ovale infections. All three 
patients had taken atovaquone-proguanil for malaria chemo­
prophylaxis; however, one had not completed the drug 
regimen, and no adherence information was available for 
the remaining two. The patient with the fourth mixed-
infection case (P. ovale and P. falciparum) had traveled to 
Papua New Guinea and also did not complete the malaria 
chemoprophylaxis drug regimen. 
Purpose of Travel 
Purpose of travel to areas in which malaria is endemic 
was reported for 617 (86.5%) of the 713 U.S. civilians 
with imported malaria. Though travelers could report mul­
tiple reasons for travel, the largest proportion (50.9%) rep­
resented persons who had visited friends or relatives in 
malarious areas; the second and third highest proportions, 
9.9% and 7.4%, represented persons who had traveled as 
missionaries or as tourists, respectively (Table 6). 
Malaria in Children 
Of the 1,445 cases for whom age was known, 280 
(19.4%) cases occurred in persons aged <18 years. Among 
these, 113 (40.4%) cases occurred among U.S. civilian 
children, 78 (27.9%) occurred among children of foreign 
citizenship, and for 89 (31.8%) cases, resident status was 
unknown. 
Ninety-four (83.1%) of the cases among U.S. civilian 
children for whom country of exposure was known were 
attributable to Africa. Of the 113 cases among U.S. civil­
ian children, six (5.3%) of the children were aged 
<24 months, 24 (21.2%) were aged 24–59 months, 40 
(35.4%) were aged 5–12 years, and 24 (21.2%) were aged 
13–17 years. Among 75 patients for which reason for travel 
was known, 74 were reported as visiting friends and rela­
tives; the remaining patient was reported as a being a tour­
ist. Among the 88 cases for whom chemoprophylaxis 
information was known, 30 (34%) patients reported tak­
ing chemoprophylaxis, of whom 18 (60%) had taken a 
correct regimen; only three (16.7%) reported complete ad­
herence. 
Malaria During Pregnancy 
A total of 17 cases of malaria were reported among preg­
nant women in 2006, representing 3.4% of cases among 
women. Eight (47.0%) of the 17 cases occurred among 
U.S. civilians, five of whom had traveled to Africa and three 
of whom had traveled to countries in Central America and 
South America. The five women who traveled to Africa were 
reported as visiting friends and relatives; the three women 
who traveled to Central America and South America were 
reported as being tourists. Of the eight cases of malaria 
reported among U.S. civilian pregnant women, only one 
(12.5%) woman reported taking malaria chemoprophy­
laxis; however, she reported taking an inappropriate medi­
cation. No information was available on the birth outcomes 
of the pregnant women. 
Deaths Attributed to Malaria 
Six deaths attributable to malaria were reported in 2006 
and are described in the following case reports: 
Case 1 
On March 20, a man aged 47 years from Thailand 
arrived in New York City and developed fever and lethargy. 
He had a medical history of alcoholic cirrhosis, ascites, spon­
taneous bacterial peritonitis, and diabetes. On March 21, 
the patient was admitted to the hospital and had symp­
toms of a chronically ill person, with fever, jaundice, and a 
distended abdomen. The initial diagnosis was hepatic 
encephalopathy and spontaneous bacterial peritonitis; 
peripheral blood smears were ordered to determine whether 
a concurrent malaria infection was present. The patient was 
intubated, received mechanical ventilation, and was treated 
with ceftriaxone, ampicillin/sulbactam, clindamycin, and 
dexamethasone. The blood smear was positive for P. malariae 
by microscopy, which was subsequently confirmed by PCR. 
Doxycycline and quinidine gluconate were added to the 
regimen within 24 hours of admission. The patient experi­
enced renal failure and died on March 25, 2006. 
Case 2 
On March 30, a woman aged 65 years returned to Ari­
zona from a 17-day tour of Kenya and Tanzania. Malaria 
prophylaxis had been prescribed, but the entire regimen 
was not completed. On June 7, the woman experienced 
fever and chills. On June 9, she sought treatment at an 
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emergency room; she was evaluated, received intravenous 
fluids, and was sent home. On June 12, the patient 
returned to the hospital with the same symptoms as well as 
nausea and syncope. A peripheral blood film revealed 
P. falciparum infection; the patient was administered oral 
quinine and doxycycline. On June 13, she experienced a 
decreased level of consciousness, necessitating intubation 
and mechanical ventilation. She died the same evening. 
Case 3 
On June 29, a girl aged 2 years who recently had emi­
grated from Nigeria was hospitalized in Boston, Massachu­
setts, for fever, vomiting, diarrhea, and scleral icterus. 
Peripheral blood films obtained on admission were posi­
tive for P. falciparum, with 1.4% parasitemia; she was 
administered oral atovaquone-proguanil. On June 30, her 
parasitemia increased to 26.7%, and she was transferred to 
the pediatric intensive care unit for an exchange transfu­
sion and continuous quinidine infusion plus intravenous 
clindamycin. By July 2, the parasitemia had resolved, but 
the patient experienced acute respiratory distress syndrome. 
The patient was intubated and mechanical ventilation was 
initiated; she died on July 3, 2006. 
Case 4 
On July 28, a man aged 59 years returned from a month­
long trip to Ghana. The patient also traveled regularly to 
India twice per year for mission work; his most recent trip 
had been in January 2006. He did not take malaria pro­
phylaxis routinely while in India and did not take malaria 
prophylaxis while traveling to Africa. The evening he 
returned to the United States, he experienced a high fever 
and went to an urgent care center, where he received a 
diagnosis of community-acquired pneumonia and was 
treated with azithromycin. The patient’s symptoms per­
sisted and progressed to include vomiting and melena. He 
sought medical attention again on August 1; a peripheral 
blood film revealed P. falciparum with 10% parasitemia. 
He was administered oral mefloquine and transferred to a 
hospital intensive care unit (ICU), where he was treated 
with quinine and doxycycline. Within 24 hours, he expe­
rienced respiratory distress and was intubated. Quinidine 
gluconate was recommended, and exchange transfusion was 
initiated; however the patient died before quinidine glu­
conate could be administered. The patient died on 
August 3, 2006. 
Case 5 
On October 17, a woman aged 75 years who was a resi­
dent of India arrived in Arizona to attend a family wed­
ding. On October 19, she was taken to the hospital be­
cause of fever, disorientation, and decreased level of con­
sciousness. Her medical history included a neurogenic 
bladder, necessitating self-catheterization, and cerebral 
malaria. The initial diagnosis was pyelonephritis, and she 
was treated with intravenous ceftriaxone in the ICU. On 
October 20, a peripheral blood film revealed P. falciparum; 
quinine and doxycycline were added to the treatment regi­
men. The patient experienced renal failure and acute respi­
ratory distress syndrome and was intubated on the October 
23. She experienced a nosocomial blood stream infection, 
and antibiotics were continued; however, her condition con­
tinued to deteriorate. The patient was discharged to hos­
pice care and died on November 11, 2006. 
Case 6
 Case 6 was reported as case 2 in the CDC malaria sur­
veillance report published in 2007 (7). However, the 
actual date of onset was April 19, 2006, not 2005 as previ­
ously reported. 
On April 19, a man aged 55 years was taken to an ED 
with a 4-day history of fever, emesis, and epigastric pain. He 
was a resident of the United States but had traveled to Uganda, 
his country of origin, for 3 months and had returned on 
April 12. He had not taken malaria prophylaxis. On admis­
sion, he had sinus tachycardia and a temperature of 100.3ºF 
(37.9ºC). Routine laboratory analysis was significant only 
for thrombocytopenia (platelet count: 19,000/µL). A differ­
ential diagnoses list was generated, including malaria, den­
gue fever, and Chikungunya fever; no additional evaluations 
were performed. The patient’s symptoms improved with 
antiemetics, normal saline, and pain control. He was dis­
charged with a tentative diagnosis of dengue fever. Four days 
later, on April 23, he died abruptly. Samples sent to CDC 
were positive for P. falciparum by PCR but negative for other 
suspected pathogens. 
Discussion 
A total of 1,564 cases of malaria were reported to CDC 
for 2006, representing an increase from the total number 
of cases reported in 2005. The number of cases with no 
information regarding residential status or clinical infor­
mation increased from 2005 to 2006, from 325 unidenti­
fied cases to 634 unidentified cases (7). Excluding the cases 
with no information on residence status, the percentage of 
U.S. resident cases was relatively stable from 2000 to 2006. 
Although during 2002–2006, the number of cases 
acquired from specific regions overall was stable, the pro­
portion of cases from Asia increased slightly but steadily. 
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Flux in the number of cases acquired in a specific region 
can be affected by many factors, including the amount of 
transmission occurring in the region, adherence to preven­
tive measures (e.g., mosquito avoidance and chemoprophy­
laxis) by travelers, the purpose of travel that predominates 
in that country (e.g., business travel or adventure travel), 
and the volume of travel to those countries. 
Of the 1,564 imported cases, 634 (40.5%) cases did not 
have information available regarding residential status, and 
424 (27.1%) did not have information regarding travel 
history. An increase in the number of cases that do not 
have residential and clinical information available decreases 
the accuracy with which the data reflect trends in malaria 
surveillance in the United States. Vigilance needs to be 
exercised by local and state health departments, health-care 
providers, and other health personnel to provide 
accompanying information regarding malaria cases when sub­
mitting cases through the various reporting systems to CDC. 
In the Caribbean region, the endemic transmission of 
malaria ended in the mid-1960s, except in the island of 
Hispaniola, which includes the countries of Dominican 
Republic and Haiti (8). In 2006, three cases of malaria in 
the United States were reported from the Caribbean region; 
two in U.S. travelers and one in a foreign visitor. Two of the 
three cases were acquired from Jamaica and one from The 
Bahamas (Great Exuma Island); all were caused by 
P. falciparum. Although these countries were not consid­
ered risk areas for malaria, the islands remained at risk for 
reintroduction because of the tropical climate, presence of 
viable vectors, and close proximity to countries where 
malaria is still endemic. As a result, CDC issued recom­
mendations on June 16, 2006, and December 4, 2006, for 
chloroquine chemoprophylaxis for persons traveling to Great 
Exuma, The Bahamas, and Kingston, Jamaica, respectively. 
Through several interventions, including active case find­
ing and treatment and mosquito-control strategies, the 
outbreak in Great Exuma seemed to be controlled. CDC 
rescinded chemoprophylaxis recommendations for travel­
ers to Great Exuma on September 19, 2006 (9). However, 
additional cases have occurred in travelers, and chemopro­
phylaxis recommendations have been reinstated. In Jamaica, 
similar strategies to contain the outbreak have been used; 
however, rare cases continue to be identified in Kingston.§ 
Fortunately, these occasional cases do not present a sub­
stantial ongoing risk to travelers, and routine chemopro­
phylaxis is no longer recommended. Both of these outbreaks 
§ Additional information on the malaria outbreak in Jamaica is available 
from the World Health Organization at http://www.who.int/csr/don/ 
2007_02_09/en/index.html. 
demonstrate the importance of the constant vigilance of 
health-care providers and rapid response by public health 
officials for effective containment strategies to avoid wide­
spread reintroduction of malaria in nonendemic areas. 
U.S. military personnel usually are on long-term pro­
phylaxis for malaria to adequately protect them for the 
duration of their deployment in malaria-endemic regions. 
In regions where P. vivax or P. ovale infections predominate, 
primaquine is recommended in addition to the chemopro­
phylactic regimen to prevent relapsing malaria infection 
(10). The U.S. Army recommends that U.S. soldiers being 
deployed in regions where P. vivax infections predominate 
should take mefloquine or doxycycline as the primary pro­
phylactic drug, followed by primaquine for 2 weeks before 
their return to the United States (11,12). In 2006, 19 of 
25 soldiers who had long-term (>1 year) deployments in 
Afghanistan had not taken primaquine terminal prophy­
laxis after their course of doxycycline as prescribed by the 
U.S. Army. Of the remaining six soldiers who had taken 
both doxycycline and primaquine chemoprophylaxis, only 
one soldier reported adherence to the entire regimen. 
One purpose of malaria surveillance is to identify pro­
phylaxis failures that might indicate emergence of drug 
resistance. However, approximately 82% of imported 
malaria cases among U.S. residents for whom information 
regarding prophylaxis use was available occurred among per­
sons who were either not taking prophylaxis or were taking 
a non-CDC recommended prophylaxis regimen. Based on 
available information, the majority of patients who appar­
ently received an appropriate medication and had onset of 
symptoms within 45 days, reported nonadherence with their 
chemoprophylactic regimen or provided insufficient infor­
mation to make a determination regarding adherence. 
Because CDC does not actively seek serum drug levels from 
patients who report adherence with a recommended regi­
men, differentiating among inaccurate reporting of adher­
ence, malabsorption of the antimalarial drug, and emerging 
drug resistance is not possible. No conclusive evidence 
indicates a single national or regional source of infection in 
this group of patients or the failure of a particular chemo­
prophylactic regimen. Health-care providers are encouraged 
to contact CDC quickly when chemoprophylaxis failure is 
suspected to enable CDC to measure serum drug levels of 
the antimalarial drugs in question and parasite from the 
patient to evaluate for possible drug resistance. 
Of the six fatal cases that occurred in the United States 
in 2006, four of the patients reported taking no chemo­
prophylaxis while traveling to areas where malaria is 
endemic; information on chemoprophylaxis use for the 
remaining two cases was not available. One patient sub­
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stantially delayed seeking care, five had substantial delays in 
establishing a diagnosis, and three patients experienced a 
delay in receiving appropriate treatment. These findings 
underscore the importance of patients adhering to correct 
chemoprophylaxis and promptly seeking medical care if 
symptoms develop, as well as the importance of physicians 
considering malaria in the differential diagnosis of fever in 
a person who has returned from travel. A previous review of 
deaths attributed to malaria in the United States indicated 
that failure to take or adhere to recommended antimalarial 
chemoprophylaxis, promptly seek medical care for posttravel 
illness, and promptly diagnose and treat suspected malaria 
all contributed to fatal outcomes (13). 
As in previous years, people who traveled to visit friends 
and relatives experienced the majority of malaria cases in 
2006. Foreign-born U.S. civilians need to be aware that 
acquired immunity wanes quickly when malaria exposure 
is interrupted and that they need to take prophylaxis when 
returning to malarious areas. Additionally, children of 
foreign-born U.S. civilians who are born in the United States 
are not immune to malaria and are highly vulnerable to 
infection (14). In this summary, approximately three fourths 
of the children with malaria whose reason for travel was to 
visit friends and relatives abroad had not been taking any 
chemoprophylaxis or had been taking an incorrect medica­
tion for chemoprophylaxis. 
Seventeen cases were reported in pregnant women, a 21% 
increase from 2005. Among U.S. civilians who were preg­
nant, only one of eight women (12.5%) reported taking 
chemoprophylaxis. This proportion is much lower than the 
percentage of total U.S. civilians with malaria who took 
chemoprophylaxis. Malaria during pregnancy among 
women who are not immune poses a high risk for both 
maternal and perinatal morbidity and mortality (15). Preg­
nant travelers should be counseled to avoid travel to 
malarious areas. If deferral of travel is impossible, these 
women should be informed that the risks from malaria 
greatly outweigh those associated with prophylaxis and that 
safe chemoprophylaxis regimens are available and should 
be emphasized. Information for pregnant travelers is avail­
able at http://wwwn.cdc.gov/travel/contentmalariapregnant 
public.aspx. 
Signs and symptoms of malaria are often nonspecific, but 
fever usually is present. Other symptoms include headache, 
chills, increased sweating, back pain, myalgia, diarrhea, 
nausea, vomiting, and cough. For prompt diagnosis, 
malaria must be included in the differential diagnosis of 
illness in a febrile patient with a history of travel to a 
malarious area. Clinicians should ask all febrile patients for 
a travel history, including international visitors, immigrants, 
refugees, migrant laborers, and other international travelers. 
Prompt treatment of suspected malaria is essential 
because persons with P. falciparum infection are at risk for 
experiencing life-threatening complications soon after 
onset of illness. Ideally, therapy for malaria should be initi­
ated immediately after the diagnosis has been made. Treat­
ment should be determined on the basis of the infecting 
Plasmodium species, the probable geographic origin of the 
parasite, the parasite density, and the patient’s clinical sta­
tus (15). If malaria is suspected but cannot be confirmed 
or malaria is confirmed but species determination is not 
possible, antimalarial treatment that is effective against 
P. falciparum should be initiated. Resistance of P. falciparum 
to chloroquine occurs worldwide, with the exception of a 
limited number of geographic regions (e.g., Central 
America). Therefore, therapy for presumed P. falciparum 
malaria should entail the use of a drug effective against 
such resistant strains (16). 
The findings in this report are subject to at least two 
limitations. First, although malaria is a notifiable disease 
in the United States, malaria case counts are obtained 
through passive surveillance systems and from individual 
reporting from health-care professionals treating persons 
with malaria. Therefore, only cases that are diagnosed by 
health-care or laboratory workers and reported to state and 
local health departments and to CDC are included, possi­
bly resulting in an underestimate of disease incidence. Sec­
ond, the completeness of reporting to the surveillance 
system might vary by reporting group and by year, which 
limits the amount of information that can be learned from 
each case. 
Health-care providers should be familiar with prevention, 
recognition, and treatment of malaria and are encouraged 
to consult appropriate sources for malaria prevention and 
treatment recommendations (Table 7). Physicians seeking 
assistance with the diagnosis or treatment of patients with 
suspected or confirmed malaria should call CDC’s Malaria 
Branch (telephone: 770-488-7788; Monday–Friday, 
8:00 AM–4:30 PM EST); call CDC’s Emergency Opera­
tions Center (telephone: 770-488-7100) during evenings, 
weekends, and holidays (ask to page person on call for 
Malaria Branch); or visit CDC’s website at http://www.cdc. 
gov/malaria/diagnosis_treatment/treatment.htm. These 
resources are intended for use by health-care providers only. 
Detailed recommendations for the public for preventing 
malaria are available online at http://wwwn.cdc.gov/travel/ 
contentdiseases.aspx#malaria. In addition, biannually, 
CDC publishes recommendations in Health Information for 
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International Travel (commonly referred to as The Yellow 
Book) (17), which is available and updated frequently on 
CDC’s website at http://wwwn.cdc.gov/travel; The Yellow 
Book also can be purchased online from Elsevier at http:// 
www.elsevierhealth.com or by telephone (800-545-2522). 
CDC provides assistance for diagnostic parasitology 
through DPDx (Laboratory Identification of Parasites of 
Public Health Concern), a project developed and main­
tained by CDC’s Division of Parasitic Diseases. DPDx 
(available at http://www.dpd.cdc.gov/dpdx) provides free 
Internet-based laboratory diagnostic assistance (i.e., 
telediagnosis) to laboratorians and pathologists in suspected 
parasitic disease cases, such as malaria. Digital images cap­
tured from diagnostic specimens can be submitted for con­
sultation through e-mail. Telediagnosis assistance by CDC 
is available during regular business hours. Because labora­
tories can transmit images to CDC and obtain a rapid 
response (with average time ranging from minutes to sev­
eral hours) to their inquiries, this system allows efficient 
diagnosis of challenging cases and rapid dissemination of 
information. As of January 2008, approximately 49 public 
health laboratories in 46 states and Puerto Rico had the 
ability to perform telediagnosis. Implementation of 
telediagnosis at public health laboratories receives full 
assistance from CDC, including training of personnel in 
digital imaging techniques. The DPDx website also con­
tains reference material with images, text, and videos on 
approximately 100 different species of parasites with infor­
mation (including laboratory diagnosis, geographic distri­
bution, clinical features, treatment, and life cycles) available 
for each parasite. 
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FIGURE 1. Number of malaria cases,* by state in which the 


































































* N=1,561. No state was reported for three cases. 
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FIGURE 2. Number of imported malaria cases and estimated relative case rates* among U.S. civilians, by country of acquisition — 
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* Using estimates of travel volume for U.S. travelers to each country from which cases of malaria were acquired, and the number of cases among U.S. 
travelers attributable to each country, a case rate was estimated for each country. Data used to estimate country-specific relative case rates were 
extrapolated from World Tourism Organization estimates of annual numbers of U.S. travelers to specific countries (6). Relative case rates were 
determined by dividing the individual country-specific case rate by the median individual country-specific case rate. The number of cases of malaria 
among U.S. civilian travelers attributable to each country is displayed next to the country name in parentheses. Note that certain risk estimates are 
based on small numbers of cases. 
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TABLE 1. Number of malaria cases* among U.S. and foreign TABLE 2. Number of malaria cases, by Plasmodium species — 
residents and U.S. military personnel — United States, 1976–2006 United States, 2004, 2005, and 2006 
U.S. military U.S. Foreign Status not 2004 2005 2006Plasmodium 
Year personnel civilians civilians recorded Total species No. (%) No. (%) No. (%) 
1976 5 178 227 5 415 P. falciparum 656 (49.5) 742 (48.6) 613 (39.2) 
1977 11 233 237 0 481 P. vivax 315 (23.8) 337 (22.1) 275 (17.6) 
1978 31 270 315 0 616 P. malariae 47 (3.5) 54 (3.5) 46 (2.9) 
1979 11 229 634 3 877 P. ovale 27 (2.0) 38 (2.5) 47 (3.0) 
1980 26 303 1,534 1 1,864 Mixed 17 (1.3) 12 (0.8) 10 (0.6) 
1981 21 273 809 0 1,103 Undetermined 262 (19.8) 345 (22.6) 573 (36.6) 
1982 8 348 574 0 930 Total 1,324 (100) 1,528 (100) 1,564 (100)
1983 10 325 468 0 803 
1984 24 360 632 0 1,016 
1985 31 446 568 0 1,045 
1986 35 410 646 0 1,091 
1987 23 421 488 0 932 
1988 33 550 440 0 1,023 
1989 35 591 476 0 1,102 
1990 36 558 504 0 1,098 
1991 22 585 439 0 1,046 
1992 29 394 481 6 910 
1993 278 519 453 25 1,275 
1994 38 524 370 82 1,014 
1995 12 599 461 95 1,167 
1996 32 618 636 106 1,392 
1997 28 698 592 226 1,544 
1998 22 636 361 208 1,227 
1999 55 833 381 271 1,540 
2000 46 827 354 175 1,402 
2001 18 891 316 158 1,383 
2002 33 849 272 183 1,337 
2003 36 767 306 169 1,278 
2004 32 775 282 235 1,324 
2005 36 870 297 325 1,528 
2006 50 663 217 634 1,564 
* A case was defined as symptomatic or asymptomatic illness that 
occurs in the United States or one of its territories in a person who has 
laboratory-confirmed malaria parasitemia (by microscopy or 
polymerase chain reaction), regardless of whether the person had 
previous attacks of malaria while in other countries. A subsequent 
attack of malaria occurring in a person is counted as an additional 
case if the demonstrated Plasmodium species differs from the initially 
identified species or if it is indicated as a relapsing infection 
demonstrating the same species identified previously. A subsequent 
attack of malaria occurring as a result of drug resistance or other 
treatment failure is not counted as an additional case. 
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TABLE 3. Imported malaria cases, by country of acquisition and Plasmodium species — United States, 2006 
Country Plasmodium species 
of acquisition P. falciparum P. vivax P. malariae P. ovale Unknown Mixed Total 
Africa 522 34 34 37 159 7 793 
Angola 1 0 0 0 1 0 2 
Benin 2 1 0 0 4 0 7 
Burkina Faso 4 0 3 0 0 0 7 
Cameroon 14 3 0 0 6 1 24 
Chad 3 1 0 0 1 0 5 
Congo 3 1 1 3 3 1 12 
Côte d’Ivoire 11 1 0 3 5 0 20 
Democratic Republic of Congo 0 0 0 1 0 0 1 
Egypt 1 0 0 0 0 0 1 
Equatorial Guinea 0 0 0 0 4 0 4 
Eritrea 0 0 0 1 0 0 1 
Ethiopia 0 4 1 0 4 0 9 
Gambia 2 0 0 0 1 0 3 
Ghana 85 4 6 4 17 0 116 
Guinea 21 0 2 1 6 0 30 
Kenya 15 0 2 1 5 0 23 
Liberia 20 0 1 2 6 0 29 
Madagascar 0 0 1 0 0 1 2 
Malawi 4 0 0 0 1 0 5 
Mali 13 0 0 0 2 0 15 
Mozambique 3 0 0 1 2 0 6 
Niger 3 0 1 0 0 0 4 
Nigeria 202 8 5 11 50 2 278 
Senegal 15 0 0 0 0 0 15 
Sierra Leone 28 1 0 0 3 1 33 
Somalia 0 0 1 0 0 0 1 
South Africa 3 0 0 0 2 0 5 
Sudan 2 2 0 0 3 0 7 
Tanzania 4 0 1 0 3 0 8 
Togo 4 0 0 0 2 0 6 
Uganda 24 5 5 4 11 0 49 
Zambia 2 0 0 0 0 0 2 
Zimbabwe 1 0 0 0 1 0 2 
West Africa, unspecified 14 1 1 0 8 0 24 
East Africa, unspecified 0 0 0 1 0 0 1 
Africa, unspecified 18 2 3 4 8 1 36 
Asia 19 126 7 1 50 2 205 
Afghanistan 0 34 0 0 8 0 42 
Burma (Myanmar) 0 1 0 0 0 0 1 
Cambodia 3 0 0 0 1 0 4 
China 1 0 0 0 0 0 1 
India 9 75 4 1 32 0 121 
Indonesia 4 2 0 0 2 0 8 
Iraq 0 1 1 0 2 0 4 
Korea (South) 0 3 0 0 1 0 4 
Pakistan 1 6 1 0 0 0 8 
Philippines 1 0 0 0 0 0 1 
Saudi Arabia 0 0 0 0 1 0 1 
Thailand 0 2 1 0 2 2 7 
Vietnam 0 1 0 0 0 0 1 
Asia, unspecified 0 1 0 0 1 0 2 
Central America 
and the Caribbean 25 44 1 1 11 0 82 
Bahamas 1 0 0 0 0 0 1 
Belize 0 0 0 1 0 0 1 
Costa Rica 0 2 0 0 1 0 3 
Dominican Republic 2 0 0 0 1 0 3 
El Salvador 0 1 0 0 0 0 1 
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TABLE 3. (Continued) Imported malaria cases, by country of acquisition and Plasmodium species — United States, 2006 
Country Plasmodium species 
of acquisition P. falciparum P. vivax P. malariae P. ovale Unknown Mixed Total 
Central America 
and the Caribbean (cont’d.) 
Guatemala 0 11 0 0 5 0 16 
Haiti 14 0 1 0 0 0 15 
Honduras 5 29 0 0 2 0 36 
Jamaica 2 0 0 0 0 0 2 
Nicaragua 1 1 0 0 2 0 4 
North America 0 7 0 0 4 0 11 
Mexico 0 7 0 0 4 0 11 
South America 2 19 1 2 3 0 27 
Bolivia 0 1 0 0 0 0 1 
Brazil 0 10 0 1 2 0 13 
Ecuador 1 4 0 0 0 0 5 
Guyana 1 1 0 0 1 0 3 
Peru 0 1 1 0 0 0 2 
Suriname 0 1 0 0 0 0 1 
South America, unspecified 0 1 0 1 0 0 2 
Oceania 1 16 0 0 4 1 22 
Papua New Guinea 1 12 0 0 3 1 17 
Vanuatu 0 4 0 0 1 0 5 
Unknown 44 29 3 6 342 0 424 
Total 613 275 46 47 573 10 1,564 
TABLE 4. Number of imported malaria cases among U.S. and 
foreign residents, by region of acquisition — United States, 2006* 
United States Foreign Total 
Area or region No. (%) No. (%) No. (%) 
Africa 511 (71.7) 131 (60.3) 642 (69.0) 
Asia 116 (16.3) 52 (24.0) 168 (18.1) 
Central America 
and the Caribbean 42 (5.9) 25 (11.5) 67 (7.2) 
South America 18 (2.5) 3 (1.4) 21 (2.3) 
North America 4 (0.5) 2 (0.9) 6 (0.6) 
Oceania 17 (2.4) 1 (0.5) 18 (1.9) 
Unknown† 5 (0.7) 3 (1.4) 8 (0.9) 
Total 713 (100) 217 (100) 930 (100) 
*Persons for whom U.S. or foreign status is not known are excluded.
†Region of acquisition is unknown. 
TABLE 5. Number of imported malaria cases, by interval between date of arrival in the country and illness onset and by Plasmodium 
species* — United States, 2006 
P. falciparum P. vivax P. malariae P. ovale Mixed Total 
Interval (days) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
<0† 32 (7.4) 5 (3.9) 1 (3.1) 2 (7.4) 0 (0) 40 (6.5) 
0–29 384 (89.5) 69 (54.3) 22 (68.7) 14 (51.9) 7 (100) 496 (79.7) 
30–89 13 (3.0) 16 (12.6) 6 (18.7) 4 (14.8) 0 (0) 39 (6.3) 
90–179 0 (0) 14 (11.0) 3 (9.4) 2 (7.4) 0 (0) 19 (3.0) 
180–364 0 (0) 19 (15.0) 0 (0) 3 (11.1) 0 (0) 22 (3.5) 
>365 0 (0) 4 (3.1) 0 (0) 2 (7.4) 0 (0) 6 (1.0) 
Total 429 (100) 127 (100) 32 (100) 27 (100) 7 (100) 622 (100.0) 
* Persons for whom Plasmodium species, date of arrival in the United States, or date of onset of illness is unknown are not included.
†Persons with cases in this row had onset of illness before arriving in the United States. 
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TABLE 6. Number of imported malaria cases among U.S. 
civilians, by purpose of travel at time of acquisition — United 
States, 2006 
Imported cases 
Purpose of travel No. (%)* 
Visiting friends/relatives 363 (50.9) 
Tourism 71 (9.9) 
Missionary or dependent 53 (7.4) 
Business representative 41 (5.7) 
Student/teacher 26 (3.6) 
Peace Corps volunteer 5 (0.7) 
Air crew/sailor 4 (0.6) 
Other/mixed purpose 18 (2.5) 
Unknown 132 (18.5) 
* Percentages do not equal 100% because travelers can identify multiple 
reasons for purpose of travel. 





CDC Travelers’ Health website (includes 
online access to Health Information for 
International Travel [The Yellow Book]) 
Availability 
24 hours/day 
Telephone number, website, or e-mail address 
http://www.cdc.gov/travel 
Prophylaxis Health Information for International Travel 
(The Yellow Book) 
Order from: 
Elsevier, Health Sciences 
Division Order Fulfillment 
11830 Westline Industrial Drive 
St. Louis, MO 63146 
800-545-2522 or 
http://www.elsevier.com 
Prophylaxis CDC Malaria Risk Map 24 hours/day http://www.cdc.gov/malaria/features/risk_map.htm 
Diagnosis CDC, Division of Parasitic Diseases website: 
Laboratory Identification of Parasites of 
Public Health Concern (DPDx) 
24 hours/day http://www.dpd.cdc.gov/dpdx 
Diagnosis CDC, Division of Parasitic Diseases diagnostic 
CD-ROM (DPDx) 
Order by e-mail from CDC, 
Division of Parasitic 
Diseases 
dpdx@cdc.gov 
Treatment* CDC Malaria Branch 8:00 A.M.–4:30 P.M. EST, 
Monday–Friday 
770-488-7788* 
Treatment* CDC Malaria Branch 4:30 P.M.–8:00 A.M. EST, 
on weekdays; all day on 
weekends and holidays 
770-488-7100* (Telephone number for CDC 
Director’s Emergency Operations Center. Ask a 
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